Patent application title: Lyophilized DNA Formulations for Enhanced Expression of Plasmid DNA
Inventors:
Jong-Mook Kim (Seoul, KR)
Jong-Mook Kim (Seoul, KR)
Sujeong Kim (Seoul, KR)
Woong Hahn (Goyang-Si, KR)
Wonsun Yoo (Seoul, KR)
IPC8 Class: AA61K317088FI
USPC Class:
514 44 R
Class name:
Publication date: 2009-10-15
Patent application number: 20090258932
Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
Patent application title: Lyophilized DNA Formulations for Enhanced Expression of Plasmid DNA
Inventors:
JONG-MOOK KIM
SUJEONG KIM
WOONG HAHN
WONSUN YOO
Agents:
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
Assignees:
Origin: WASHINGTON, DC US
IPC8 Class: AA61K317088FI
USPC Class:
514 44 R
Patent application number: 20090258932
Abstract:
The present invention provides for a method of treating or preventing
ischemic or liver disease in a subject by administering a composition
reconstituted from a lyophilized hepatocyte growth factor (HGF) DNA
formulation, where the DNA formulation comprises an HGF plasmid DNA, salt
and a carbohydrate. The invention further provides for a method of making
such a lyophilized DNA formulation that preserves or enhances gene
expression both in vitro and in vivo, thus maintaining or stimulating the
biological activity of the expressed protein. The invention also provides
for the DNA formulation, or the lyophilized DNA formulation according to
the methods disclosed.Claims:
1. A DNA formulation comprising a plasmid DNA, a salt and a carbohydrate,
wherein said plasmid DNA comprises an HGF gene, or variant thereof.
2. The DNA formulation of claim 1, wherein said carbohydrate is a mono-, oligo-, or polysaccharide selected from the group consisting of sucrose, glucose, lactose, trehalose, arabinose, pentose, ribose, xylose, galactose, hexose, idose, mannose, talose, heptose, fructose, gluconic acid, sorbitol, mannitol, methyl α-glucopyranoside, maltose, lactone, sorbose, glucaric acid, erythrose, threose, allose, altrose, gulose, erythrulose, ribulose, xylulose, psicose, tagatose, glucuronic acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, neuraminic acid, arabinans, fructans, fucans, galactans, galacturonans, glucans, mannans, xylans, levan, fucoidan, carrageenan, galactocarolose, pectins, pectic acids, amylose, pullulan, glycogen, amylopectin, cellulose, dextran, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xantham gum, starch, and admixtures thereof.
3. The DNA formulation of claim 1, wherein said carbohydrate is in an amount selected from the group consisting of between about 0.05% to about 30%, between about 0.1% to about 15%, between about 0.2% to about 10%, between about 0.5% and 5%, between about 0.75% and 3%, between about 0.8% and 2%, and between about 0.8% and 1.5%.
4. The DNA formulation of claim 3, wherein said carbohydrate is in an amount of about 0.1% to about 10%.
5. (canceled)
6. The DNA formulation of claim 2, wherein said carbohydrate is selected from the group consisting of sucrose, mannitol, and admixture thereof.
7. The DNA formulation of claim 1, wherein said salt is selected from the group consisting of NaCl, KCl, and admixture thereof.
8. The DNA formulation of claim 1, wherein said salt is in an amount selected from the group consisting of between about 0.001% and about 10%, between about 0.1% and 5%, between about 0.5% and 2%, between about 0.8% and 1.5%, and between about 0.8% and 1.2%.
9. (canceled)
10. The DNA formulation of claim 1, wherein said HGF gene or variant thereof is selected from the group consisting of flHGF, dHGF, NK1, NK2, NK4, and admixtures thereof.
11. The DNA formulation of claim 1, wherein said plasmid DNA comprises a hybrid HGF gene.
12. The DNA formulation of claim 11, wherein said hybrid HGF gene is selected from the group consisting of HGF-X2, HGF-X3, HGF-X6, HGF-X7, and HGF-X8.
13. The DNA formulation of claim 12, wherein said plasmid DNA is selected from the group consisting of: pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X6, pCK-HGF-X7, pCK-HGF-X8, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8.
14. The DNA formulation of claim 1, wherein said plasmid DNA is at a concentration of about 1 ng/mL to about 30 mg/mL.
15. (canceled)
16. (canceled)
17. The DNA formulation of claim 1, wherein said DNA formulation is lyophilized.
18. The lyophilized DNA formulation of claim 17, wherein the lyophilization of said DNA formulation comprises (a) loading a container with said DNA formulation into a lyophilizer; (b) cooling said DNA formulation to a subzero temperature; and (c) drying said DNA formulation.
19-21. (canceled)
22. A method of treating or preventing ischemic or liver disease in a subject, comprising administering a composition reconstituted from a lyophilized DNA formulation,wherein said lyophilized DNA formulation comprises a plasmid DNA, a salt and a carbohydrate; andwherein said plasmid DNA comprises an HGF gene, or variant thereof.
23-37. (canceled)
38. The method of claim 22, wherein said lyophilized DNA is reconstituted in a pharmaceutically acceptable solution.
39. The method of claim 38, wherein said pharmaceutically acceptable solution is selected from the group consisting of water, PBS, TE, Tris buffer, normal saline, and admixtures thereof.
40. The method of claim 22, wherein said reconstituted composition is administered by direct injection.
41. A method of making a lyophilized DNA formulation comprising:(a) preparing a DNA formulation comprising a plasmid DNA, a salt and a carbohydrate, wherein said plasmid DNA comprises an HGF gene, or variant thereof; and(b) lyophilizing said DNA formulation, thereby making said lyophilized DNA formulation.
42. The method of claim 41, wherein the lyophilization of said DNA formulation further comprises (a) loading a container with said DNA formulation into a lyophilizer; (b) cooling said DNA formulation to a subzero temperature; and (c) drying said DNA formulation.
43. (canceled)
44. (canceled)
Description:
[0001]This application claims priority to U.S. Provisional Appl. No.
61/043,605, filed on Apr. 9, 2008, the entire contents of which are
hereby incorporated by reference in their entirety.
REFERENCE TO A SEQUENCE LISTING SUBMITTED ELECTRONICALLY VIA EFS-WEB
[0002]The content of the electronically submitted sequence listing (Name: Sequence_Listing_Ascii.txt, Size: 68,654 bytes; and Date of Creation: Apr. 8, 2009) filed herewith the application is incorporated by reference in its entirety.
BACKGROUND OF THE INVENTION
[0003]Lyophilization is often a preferred formulation for therapeutic materials because the long-term stability of many materials increases in the lyophilized state. However, for plasmid DNA, lyophilized formulations are not the formulations of choice. In most clinical trials using naked (non-complexed plasmid) DNA as a delivery vector, the preferred formulation has been a liquid formulation.
[0004]While lyophilized plasmid DNA may be a preferred form of storage, lyophilized formulations for plasmid DNA have been considered to cause a reduction in gene expression efficiency. Lyophilization causes the removal of the hydration sphere around a molecule. For DNA, it appears that there are approximately 20 water molecules per nucleotide pair bound most tightly to DNA that do not form an ice-like structure upon low-temperature cooling. Upon DNA dehydration over hygroscopic salts at 0% relative humidity, only five or six water molecules remain. Thus, lyophilization may increase the stability of DNA under long-term storage, but may also cause some damage upon the initial lyophilization process, potentially through changes in the DNA secondary structure or the concentration of reactive elements such as contaminating metals. Therefore, a potential mechanism for loss of gene expression efficiency of lyophilized plasmid DNA may be through a gross structural change to the plasmid.
[0005]In Poxon et al, Pharmaceutical Development and Technology 5:115-122 (2000), the authors demonstrated that lyophilization of a plasmid DNA (pRL-CMV) resulted in a statistically significant loss of transfection efficiency. A biofunctionality assay, measuring transfection activity, demonstrated a loss of more than 75% of plasmid DNA activity after lyophilization as compared to control plasmid that remained in solution. While Poxon et al used carbohydrates to ameliorate the in vitro decreased transfection activity of a non-therapeutic plasmid, pRL-CMV expressing Renilla luciferase, stored in EDTA buffer, Poxon et al did not address the use of lyophilized naked DNA formulations in vivo for disease treatment or prevention.
[0006]Therefore, there is a need in the art for a stable lyophilized formulation that will not affect gene expression efficiency. The present invention provides for a lyophilized formulation for plasmid DNA that not only preserves the biological activity of the expressed gene but, in certain instances, is able to enhance biological activity.
BRIEF SUMMARY OF THE INVENTION
[0007]The present invention is directed to a lyophilized DNA formulation. In one aspect of the invention, a DNA formulation, prior to lyophilization, comprises a plasmid DNA, salt and a carbohydrate; and where the plasmid DNA comprises an HGF gene, or variant thereof. In another aspect of the invention, the DNA formulation is lyophilized. In another aspect of the invention, the lyophilized DNA formulation is reconstituted.
[0008]In one embodiment, the carbohydrate of the DNA formulation of the present invention is a mono-, oligo-, or polysaccharide such as sucrose, glucose, lactose, trehalose, arabinose, pentose, ribose, xylose, galactose, hexose, idose, mannose, talose, heptose, fructose, gluconic acid, sorbitol, mannitol, methyl α-glucopyranoside, maltose, isoascorbic acid, ascorbic acid, lactone, sorbose, glucaric acid, erythrose, threose, allose, altrose, gulose, erythrulose, ribulose, xylulose, psicose, tagatose, glucuronic acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, neuraminic acid, arabinans, fructans, fucans, galactans, galacturonans, glucans, mannans, xylans, levan, fucoidan, carrageenan, galactocarolose, pectins, pectic acids, amylose, pullulan, glycogen, amylopectin, cellulose, dextran, cyclodextrin, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xantham gum, or starch.
[0009]In certain embodiments of the invention, the carbohydrate is sucrose or mannitol.
[0010]In another embodiment, the carbohydrate of the DNA formulation of the present invention is in an amount selected from the group consisting of between about 0.05% to about 30%, between about 0.1% to about 15%, between about 0.2% to about 10%, between about 0.5% and 5%, between about 0.75% and 3%, between about 0.8% and 2%, and between about 0.8% and 1.5%. In particular embodiments, the carbohydrate is sucrose or mannitol. In certain other embodiments, the carbohydrate of the DNA formulation is in an amount of about 1.1%.
[0011]In another embodiment, the salt of the DNA formulation is selected from the group consisting of NaCl or KCl. In further embodiments, the salt of the DNA formulation is in an amount selected from the group consisting of between about 0.01% and 10%, between about 0.1% and 5%, between about 0.1% and 4%, between about 0.5% and 2%, between about 0.8% and 1.5%, between about 0.8% and 1.2% w/v. In certain embodiments, the salt of the DNA formulation is in an amount of about 0.9% w/v.
[0012]In another embodiment, the plasmid DNA of the invention comprises an HGF gene, or variant thereof. In certain embodiments, the HGF gene is a mammalian HGF gene or variant thereof. In further embodiments, the HGF gene is a human HGF gene or variant thereof. In certain aspects of the invention, the HGF gene is a hybrid HGF gene, e.g., a hybrid HGF gene comprising HGF cDNA and an inherent or foreign intron or fragment thereof, e.g., an inherent intron 4 or fragment thereof of the human HGF gene. In particular embodiments, the hybrid HGF gene comprises HGF-X2 (SEQ ID NO: 13), HGF-X3 (SEQ ID NO: 14), HGF-X6 (SEQ ID NO: 8), HGF-X7 (SEQ ID NO: 9) or HGF-X8 (SEQ ID NO: 10). In further embodiments, the plasmid DNA comprising a hybrid HGF gene is selected from the group consisting of: pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X6, pCK-HGF-X7, pCK-HGF-X8, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8, where the HGF-X2, HGF-X3, HGF-X6, HGF-X7 and HGF-X8 correspond to SEQ ID NOs: 13-14 and 8-10, respectively.
[0013]The lyophilized DNA formulations maintain or enhance the expression of the plasmid DNA. In certain aspects, the lyophilized DNA formulation provides enhanced biological activity of the expressed protein. In certain other aspects of the invention, the enhanced expression of the plasmid DNA or the enhanced biological activity of the expressed protein is due to the presence of the carbohydrate in the formulation. In certain embodiments, this carbohydrate is sucrose or mannitol.
[0014]The invention also provides for a reconstituted lyophilized plasmid DNA formulation. In certain embodiments, the lyophilized DNA is reconstituted in a pharmaceutically acceptable solution. In further embodiments, the pharmaceutically acceptable solution is selected from the group consisting of water, PBS, TE, Tris buffer and normal saline.
[0015]In another embodiment, the plasmid DNA of the reconstituted lyophilized formulation is at a final concentration of about 1 ng/mL, about 5 ng/mL, about 10 ng/mL, about 50 ng/mL, about 100 ng/mL, about 250 ng/mL, about 500 ng/mL, about 1 μg/mL, about 5 μg/mL, about 10 μg/mL, about 50 μg/mL, about 100 μg/mL, about 200 μg/mL, about 300 μg/mL, about 400 μg/mL, about 500 μg/mL, about 600 μg/mL, about 700 μg/mL, about 800 μg/mL, about 900 μg/mL, about 1 mg/mL, about 2 mg/mL, about 2.5 mg/mL, about 3 mg/mL, about 3.5 mg/mL, about 4 mg/mL, about 4.5 mg/mL, about 5 mg/mL, about 5.5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 20 mg/mL, or about 30 mg/mL. In another embodiment, the final concentration of the plasmid DNA of the reconstituted lyophilized formulation is from about 1 ng/mL to about 30 mg/mL. In certain aspects, the final concentration of the plasmid DNA of the reconstituted lyophilized formulation is from about 100 μg/mL to about 2.5 mg/mL. In further aspects, the final concentration of the plasmid DNA of the reconstituted lyophilized formulation is from about 500 μg/mL to about 1 mg/mL.
[0016]The present invention is also directed to a method of treating or preventing ischemic or liver disease in a subject, comprising administering a composition reconstituted from a lyophilized hepatocyte growth factor (HGF) DNA formulation, where the DNA formulation comprises a plasmid DNA, salt and a carbohydrate; and where the plasmid DNA comprises an HGF gene, or variant thereof. In certain aspects, the composition reconstituted from a lyophilized HGF DNA formulation is administered by direct injection.
[0017]The present invention is further directed to a method of making a lyophilized HGF DNA formulation comprising: (a) preparing a DNA formulation comprising a plasmid DNA, a salt and a carbohydrate, where the plasmid DNA comprises an HGF gene, or variant thereof; and (b) lyophilizing the DNA formulation.
[0018]The steps for lyophilization may include subjecting a DNA formulation of the invention to the process of being frozen at subzero temperatures (e.g, -10° C. to -500° C.), and then subjected to one or more drying cycles which comprises gradually heating the DNA formulation to a temperature of about 20° C. to less than or equal to about 30° C., wherein the lyophilization occurs over a period of about 50 to about 100 hours. In a further aspect of the invention, the method for lyophilization comprises: (a) forming an aqueous DNA formulation comprising a plasmid DNA, a salt and a carbohydrate, where the plasmid DNA comprises an HGF gene, or variant thereof; (b) cooling the DNA formulation solution to a temperature of about -10° C. to about -50° C., until frozen; (c) drying the DNA formulation by heating to a temperature of about 20° C. to about 30° C.; and (d) recovering a lyophilized DNA formulation composition having a water content of from about 0.1 weight percent to about 5 weight percent based on the total weight of the recovered DNA formulation.
[0019]In certain embodiments, the DNA formulation is lyophilized under conditions comprising (a) about 30 hours to about 50 hours at a temperature greater than or equal to about -50° C. and less than about 0° C., and (b) about 20 hours to about 50 hours at a temperature greater than or equal to about 0° C. to less than or equal to about 30° C., progressively, wherein the lowest (a) temperature is about -50° C. to about -30° C. and the highest (b) temperature is between about 20° C. to about 30° C. In one aspect, the DNA formulation is lyophilized under conditions of -50° C. for 4 hours, -40° C. for 12 hours, -30° C. for 6 hours, -20° C. for 6 hours, -10° C. for 6 hours, 0° C. for 6 hours, 10° C. for 6 hours and 30° C. for 24 hours, progressively. In another aspect, the DNA formulation is lyophilized under conditions of 5° C. for 1 minute, -50° C. for 2 hours, -40° C. for 6 hours, -35° C. for 3 hours, -30° C. for 6 hours, -25° C. for 3 hours, -20° C. for 3 hours, -15° C. for 3 hours, -10° C. for 6 hours, -5° C. for 3 hours, 0° C. for 6 hours, and 30° C. for 17 hours, progressively. In another aspect, the DNA formulation is lyophilized under conditions of 5° C. for 1 minute, -10° C. for 1 minute, -20° C. for 1 minute, -30° C. for 1 minute, -50° C. for 1 minute, -50° C. for 2 hours, -45° C. for 6 hours, -40° C. for 3 hours, -35° C. for 6 hours, -30° C. for 3 hours, -25° C. for 6 hours, -20° C. for 3 hours, -15° C. for 6 hours, -10° C. for 3 hours, -5° C. for 6 hours, 0° C. for 12 hours, 10° C. for 3 hours, 20° C. for 6 hours, and 30° C. for 29 hours, progressively.
[0020]The invention is further directed to a lyophilized nucleic acid formulation or a reconstituted lyophilized nucleic acid formulation, as set forth above, where the nucleic acid is an RNA that encodes for HGF, or variant thereof.
BRIEF DESCRIPTION OF THE DRAWINGS
[0021]FIG. 1 depicts a bar graph comparing in vitro HGF expression among various formulations. HGF expression levels were measured using ELISA in culture supernatants isolated from 293T cells transfected with a lyophilized plasmid DNA pCK-HGF-X7 formulated in 0.9% NaCl at a final DNA concentration of 0.5 mg/mL, with sucrose at 0.25% (lane 3), 1.1% (lane 4), 5% (lane 5), 10% (lane 6) or 20% (lane 7) or with mannitol at 1.2% (lane 8), 4.85% (lane 9) or 10% (lane 10). Control reactions with a negative control (lane 1) and non-lyophilized DNA (lane 2) were used as comparison.
[0022]FIG. 2 depicts a bar graph comparing in vivo HGF expression between non-lyophilized and lyophilized pCK-HGF-X7. Mice were injected with 100 μg of non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7) or pCK-HGF-X7 lyophilized with 1.1% Sucrose and 0.9% NaCl (L-HGF-X7) into the tibialis cranialis. HGF expression levels were measured using ELISA in muscle tissue lysates after sacrificing the mice at day 7. HGF expression levels are shown for negative control (lane 1), non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7; lane 2), and pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7; lane 3).
[0023]FIG. 3 shows a schematic diagram of the experimental procedure using the porcine ischemic heart disease model. NL-HGF-X7 corresponds to non-lyophilized pCK-HGF-X7 containing 0.9% NaCl. L-HGF-X7 corresponds to pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl.
[0024]FIG. 4 depicts a bar graph showing the effect of non-lyophilized and lyophilized pCK-HGF-X7 on myocardial perfusion. The percent improvement of myocardial perfusion as compared to baseline is shown when the porcine ischemic heart disease model is utilized. Results are shown for pigs injected with plasmid alone (pCK; lane 1), non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7; lane 2), and pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7; lane 3).
[0025]FIG. 5 depicts a bar graph showing the effect of non-lyophilized and lyophilized pCK-HGF-X7 on wall thickening. The percent improvement on wall thickening in the injected ischemic border area of the left ventricle as compared to baseline is shown when the porcine ischemic heart disease model is utilized. Results are shown for pigs injected with plasmid alone (pCK; lane 1), non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7; lane 2), and pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7; lane 3).
DETAILED DESCRIPTION OF THE INVENTION
Definitions
[0026]The term "DNA" or "nucleic acid" or "nucleic acid fragment" refers to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide or construct. A nucleic acid or fragment thereof may be provided in linear (e.g., mRNA) or circular (e.g., plasmid) form as well as double-stranded or single-stranded forms. By "isolated" nucleic acid or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide contained in a vector is considered isolated for the purposes of the present invention. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) polynucleotides in solution. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the polynucleotides of the present invention. Isolated polynucleotides or nucleic acids according to the present invention further include such molecules produced synthetically.
[0027]As used herein, a "coding region" is a portion of nucleic acid which consists of codons translated into amino acids. Although a "stop codon" (TAG, TGA, or TAA) is not translated into an amino acid, it may be considered to be part of a coding region, but any flanking sequences, for example promoters, ribosome binding sites, transcriptional terminators, and the like, are not part of a coding region. Two or more nucleic acids or nucleic acid fragments of the present invention can be present in a single polynucleotide construct, e.g., on a single plasmid, or in separate polynucleotide constructs, e.g., on separate (different) plasmids. Furthermore, any nucleic acid or nucleic acid fragment may encode a single HGF polypeptide or fragment, derivative, or variant thereof, e.g., or may encode more than one polypeptide, e.g., a nucleic acid may encode two or more polypeptides. In addition, a nucleic acid may include a regulatory element such as a promoter, ribosome binding site, or a transcription terminator, or may encode heterologous coding regions fused to the HGF coding region, e.g., specialized elements or motifs, such as a secretory signal peptide or a heterologous functional domain.
[0028]In the case of DNA, a polynucleotide comprising a nucleic acid which encodes a polypeptide normally also comprises a promoter and/or other transcription or translation control elements operably associated with the polypeptide-encoding nucleic acid fragment. An operable association is when a nucleic acid fragment encoding a gene product, e.g., a polypeptide, is associated with one or more regulatory sequences in such a way as to place expression of the gene product under the influence or control of the regulatory sequence(s).
[0029]A DNA polynucleotide of the present invention may be a circular or linearized plasmid or vector, or other linear DNA which may also be non-infectious and nonintegrating (i.e., does not integrate into the genome of vertebrate cells). A linearized plasmid is a plasmid that was previously circular but has been linearized, for example, by digestion with a restriction endonuclease. As used herein, the terms plasmid and vector can be used interchangeably.
[0030]The term "lyophilized DNA" refers to any DNA that is prepared in dry form by rapid freezing and dehydration, in the frozen state under high vacuum. "Lyophilizing" or "lyophilization" refers to a process of freezing and drying a solution. Lyophilized DNA is often made ready for use by addition of sterile distilled water.
[0031]A "vector" refers to any vehicle for the cloning of and/or transfer of a nucleic acid into a host cell. A vector may be a replicon to which another DNA segment may be attached so as to bring about the replication of the attached segment. A "replicon" refers to any genetic element (e.g., plasmid, phage, cosmid, chromosome, virus) that functions as an autonomous unit of DNA replication in vivo, i.e., capable of replication under its own control. The term "vector" includes vehicles for introducing the nucleic acid into a cell in vitro, ex vivo or in vivo. A large number of vectors known in the art may be used to manipulate nucleic acids, incorporate response elements and promoters into genes, etc. Possible vectors include, for example, plasmids such as pBR322 or pUC plasmid derivatives, or the Bluescript vector. For example, the insertion of the DNA fragments corresponding to response elements and promoters into a suitable vector can be accomplished by ligating the appropriate DNA fragments into a chosen vector that has complementary cohesive termini. Alternatively, the ends of the DNA molecules may be enzymatically modified or any site may be produced by ligating nucleotide sequences (linkers) into the DNA termini. Such vectors may be engineered to contain selectable marker genes that provide for the selection of cells. Such markers allow identification and/or selection of host cells that express the proteins encoded by the marker.
[0032]Additional vectors include lipoplexes (cationic liposome-DNA complex), polyplexes (cationic polymer-DNA complex), and protein-DNA complexes. In addition to a nucleic acid, a vector may also comprise one or more regulatory regions, and/or selectable markers useful in selecting, measuring, and monitoring nucleic acid transfer results (transfer to which tissues, duration of expression, etc.).
[0033]The term "plasmid" refers to an extra-chromosomal element often carrying a gene that is not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear, circular, or supercoiled, of a single- or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell. As used herein, the term "plasmid" refers to a construct made up of genetic material (i.e., nucleic acids). Typically a plasmid contains an origin of replication which is functional in bacterial host cells, e.g., Escherichia coli, and selectable markers for detecting bacterial host cells comprising the plasmid.
[0034]Plasmids of the present invention may include genetic elements as described herein arranged such that an inserted coding sequence can be transcribed and translated in eukaryotic cells. In certain embodiments described herein, a plasmid is a closed circular DNA molecule.
[0035]The term "expression" refers to the biological production of a product encoded by a coding sequence. In most cases a DNA sequence, including the coding sequence, is transcribed to form a messenger-RNA (mRNA). The messenger-RNA is then translated to form a polypeptide product which has a relevant biological activity. Also, the process of expression may involve further processing steps to the RNA product of transcription, such as splicing to remove introns, and/or post-translational processing of a polypeptide product.
[0036]The term "expression vector" refers to a vector, plasmid or vehicle designed to enable the expression of an inserted nucleic acid sequence following transformation into the host. The cloned gene, i.e., the inserted nucleic acid sequence, e.g., a HGF gene or variant thereof, is usually placed under the control of control elements such as a promoter, a minimal promoter, an enhancer, or the like. Initiation control regions or promoters, which are useful to drive expression of a nucleic acid in the desired host cell are numerous and familiar to those skilled in the art. Virtually any promoter capable of driving expression of these genes can be used in an expression vector, including but not limited to, viral promoters, bacterial promoters, animal promoters, mammalian promoters, synthetic promoters, constitutive promoters, tissue specific promoters, pathogenesis or disease related promoters, developmental specific promoters, inducible promoters, light regulated promoters; including, but are not limited to, the SV40 early (SV40) promoter region, the promoter contained in the 3' long terminal repeat (LTR) of Rous sarcoma virus (RSV), the E1A or major late promoter (MLP) of adenoviruses (Ad), the human cytomegalovirus (HCMV) immediate early promoter, the herpes simplex virus (HSV) thymidine kinase (TK) promoter, the baculovirus IE1 promoter, the elongation factor 1 alpha (EF1) promoter, the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter, the phosphoglycerate kinase (PGK) promoter, the ubiquitin C (Ube) promoter, the albumin promoter, the regulatory sequences of the mouse metallothionein-L promoter and transcriptional control regions, the ubiquitous promoters (HPRT, vimentin, β-actin, tubulin and the like), the promoters of the intermediate filaments (desmin, neurofilaments, keratin, GFAP, and the like), the promoters of therapeutic genes (of the MDR, CFTR or factor VIII type, and the like), pathogenesis or disease related-promoters, and promoters that exhibit tissue specificity and have been utilized in transgenic animals, such as the elastase I gene control region which is active in pancreatic acinar cells; insulin gene control region active in pancreatic beta cells, immunoglobulin gene control region active in lymphoid cells, mouse mammary tumor virus control region active in testicular, breast, lymphoid and mast cells; albumin gene, Apo AI and Apo AII control regions active in liver, alpha-fetoprotein gene control region active in liver, alpha 1-antitrypsin gene control region active in the liver, beta-globin gene control region active in myeloid cells, myelin basic protein gene control region active in oligodendrocyte cells in the brain, myosin light chain-2 gene control region active in skeletal muscle, and gonadotropic releasing hormone gene control region active in the hypothalamus, pyruvate kinase promoter, villin promoter, promoter of the fatty acid binding intestinal protein, promoter of the smooth muscle cell β-actin, and the like. In addition, these expression sequences may be modified by addition of enhancer or regulatory sequences and the like. Non-limiting examples of expression vectors of the invention include pCK (Lee et al., Biochem. Biophys. Res. Commun. 272:230 (2000); WO 2000/040737) and pCP (pcDNA3.1, Invitrogen, USA).
[0037]A "construct" as used herein generally denotes a composition that does not occur in nature. A construct can be produced by synthetic technologies, e.g., recombinant DNA preparation and expression or chemical synthetic techniques for nucleic or amino acids. A construct can also be produced by the addition or affiliation of one material with another such that the result is not found in nature in that form.
[0038]A "gene" refers to a polynucleotide comprising nucleotides that encode a functional molecule, including functional molecules produced by transcription only (e.g., a bioactive RNA species) or by transcription and translation (e.g., a polypeptide). The term "gene" encompasses cDNA and genomic DNA nucleic acids. "Gene" also refers to a nucleic acid fragment that expresses a specific RNA, protein or polypeptide, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers to any gene that is not a native gene, comprising regulatory and/or coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. A chimeric gene may comprise coding sequences derived from different sources and/or regulatory sequences derived from different sources. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign" gene or "heterologous" gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the cell by a gene transfer procedure.
[0039]"Heterologous DNA" refers to DNA not naturally located in the cell, or in a chromosomal site of the cell. The heterologous DNA may include a gene foreign to the cell.
[0040]The phrases "isolated" or "biologically pure" refer to material that is substantially or essentially free from components which normally accompany the material as it is found in its native state. Thus, isolated peptides in accordance with the invention preferably do not contain materials normally associated with the peptides in their in situ environment.
Lyophilized DNA formulations
[0041]The DNA formulation of the invention, prior to lyophilization, is formulated with certain excipients, including a carbohydrate and a salt.
[0042]As described herein, the stability of a lyophilized formulation of DNA to be utilized as a diagnostic or therapeutic agent can be increased by formulating the DNA prior to lyophilization with an aqueous solution comprising a stabilizing amount of carbohydrate.
[0043]A carbohydrate of the DNA formulation of the invention is a mono-, oligo-, or polysaccharide, such as sucrose, glucose, lactose, trehalose, arabinose, pentose, ribose, xylose, galactose, hexose, idose, mannose, talose, heptose, fructose, gluconic acid, sorbitol, mannitol, methyl α-glucopyranoside, maltose, isoascorbic acid, ascorbic acid, lactone, sorbose, glucaric acid, erythrose, threose, allose, altrose, gulose, erythrulose, ribulose, xylulose, psicose, tagatose, glucuronic acid, galacturonic acid, mannuronic acid, glucosamine, galactosamine, neuraminic acid, arabinans, fructans, fucans, galactans, galacturonans, glucans, mannans, xylans, levan, fucoidan, carrageenan, galactocarolose, pectins, pectic acids, amylose, pullulan, glycogen, amylopectin, cellulose, dextran, cyclodextrin, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, alginic acid, xantham gum, or starch.
[0044]In one aspect, the carbohydrate is mannitol or sucrose.
[0045]The carbohydrate solution prior to lyophilization can correspond to carbohydrate in water alone, or a buffer can be included. Examples of such buffers include PBS, HEPES, TRIS or TRIS/EDTA. Typically the carbohydrate solution is combined with the DNA to a final concentration of about 0.05% to about 30% sucrose, typically 0.1% to about 15% sucrose, such as 0.2% to about 5%, 10% or 15% sucrose, preferably between about 0.5% to 10% sucrose, 1% to 5% sucrose, 1% to 3% sucrose, and most preferably about 1.1% sucrose.
[0046]A salt of the DNA formulation of the invention is NaCl or KCl. In certain aspects, the salt is NaCl. In further aspects, the salt of the DNA formulation is in an amount selected from the group consisting of between about 0.001% to about 10%, between about 0.1% and 5%, between about 0.1% and 4%, between about 0.5% and 2%, between about 0.8% and 1.5%, between about 0.8% and 1.2% w/v. In certain embodiments, the salt of the DNA formulation is in an amount of about 0.9% w/v.
[0047]In the DNA formulation of the invention, the final concentration of DNA is from about 1 ng/mL to about 30 mg/mL of plasmid. For example, a formulation of the present invention may have a final concentration of about 1 ng/mL, about 5 ng/mL, about 10 ng/mL, about 50 ng/mL, about 100 ng/mL, about 200 ng/mL, about 500 ng/mL, about 1 μg/mL, about 5 μg/mL, about 10 μg/mL, about 50 μg/mL, about 100 μg/mL, about 200 μg/mL, about 400 μg/mL, about 500 μg/mL, about 600 μg/mL, about 800 μg/mL, about 1 mg/mL, about 2 mg/mL, about 2.5 mg/mL, about 3 mg/mL, about 3.5 mg/mL, about 4 mg/mL, about 4.5 mg/mL, about 5 mg/mL, about 5.5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 9 mg/mL, about 10 mg/mL, about 20 mg/mL, or about 30 mg mg/mL of a plasmid. In certain embodiments of the invention, the final concentration of the DNA is from about 100 μg/mL to about 2.5 mg/mL. In particular embodiments of the invention, the final concentration of the DNA is from about 0.5 mg/mL to 1 mg/mL.
[0048]The DNA formulation of the invention is lyophilized under standard conditions known in the art. A method for lyophilization of the DNA formulation of the invention may comprise (a) loading a container, e.g., a vial, with a DNA formulation, e.g., a DNA formulation comprising a plasmid DNA, a salt and a carbohydrate, where the plasmid DNA comprises an HGF gene, or variant thereof, into a lyophilizer, wherein the lyophilizer has a starting temperature of about 5° C. to about -50° C.; (b) cooling the DNA formulation to subzero temperatures (e.g., -10° C. to -50° C.); and (c) substantially drying the DNA formulation. The conditions for lyophilization, e.g., temperature and duration, of the DNA formulation of the invention can be adjusted by a person of ordinary skill in the art taking into consideration factors that effect lyophilization parameters, e.g., the type of lyophilization machine used, the amount of DNA used, and the size of the container used.
[0049]The container holding the lyophilized DNA formulation may then be sealed and stored for an extended period of time at various temperatures (e.g., room temperature to about -180° C., preferably about 2-8° C. to about -80° C., more preferably about -20° C. to about -80° C., and most preferably about -20° C.). In certain aspects, the lyophilized DNA formulations are preferably stable within a range of from about 2-8° C. to about -80° C. for a period of at least 6 months without losing significant activity. Stable storage plasmid DNA formulation can also correspond to storage of plasmid DNA in a stable form for long periods of time before use as such for research or plasmid-based therapy. Storage time may be as long as several months, 1 year, 5 years, 10 years, 15 years, or up to 20 years. Preferably the preparation is stable for a period of at least about 3 years.
HGF Plasmid DNA
[0050]The present invention provides for a lyophilized DNA formulation, where the DNA formulation, prior to lyophilization, comprises a plasmid DNA, and the plasmid DNA comprises an HGF gene, or variant thereof.
[0051]Hepatocyte growth factor (HGF) is a heparin binding glycoprotein also known as scatter factor or hepatopoietin-A. An endogenous gene encoding human HGF is located at chromosome 7q21.1 and comprises 18 exons and 17 introns, having the nucleotide sequence of SEQ ID NO: 1 (Seki T., et al., Gene 102:213-219 (1991)). A transcript of about 6 kb is transcribed from the HGF gene, and then, a polypeptide HGF precursor consisting of 728 amino acids (SEQ ID NO: 2) is synthesized therefrom. Simultaneously, a polypeptide of dHGF precursor consisting of 723 amino acids is also synthesized by an alternative splicing of the HGF gene. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a preactivated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting 723 amino acids is a polypeptide with deletion of five amino acids in the 1st kringle domain of the alpha chain, i.e., F, L, P, S and S.
[0052]HGF secreted from mesoderm-derived cells has various biological functions, e.g., 1) inducing epithelial cells into a tubular structure; 2) stimulating vascularization from endothelial cells in vitro and in vivo; 3) regeneration of liver and kidney, owing to its anti-apoptosis activity; 4) organogenesis of kidney, ovary and testis; 5) controlling osteogenesis; 6) stimulating the growth and differentiation of erythroid hematopoietic precursor cells; and 7) axon sprouting of neurons (Stella, M. C. and Comoglio, P. M., The International Journal of Biochemistry & Cell Biology 31:1357-1362 (1999)). Based on these various functions, HGF or a gene encoding HGF or a variant thereof, may be developed as a therapeutic agent for treating ischemic or liver diseases. Actually, in vivo, the HGF may exist as either HGF or dHGF, and therefore, the coexpression of HGF and dHGF is important for maximizing the therapeutic effect. A hybrid HGF gene which can simultaneously express HGF and dHGF with a high efficiency for gene therapy is an HGF variant that would be advantageous to utilize in the plasmid DNA formulation of the present invention.
[0053]The hybrid HGF gene has been previously described in Intl. Appl. No. WO 03/078568 and U.S. Publ. No. 2005/0079581 A1, the contents of each which are herein incorporated by reference. The hybrid HGF gene is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA. The hybrid HGF gene has a higher expression efficiency than HGF cDNA and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF).
[0054]The term "isoform of HGF" refers to any HGF polypeptide having an amino acid sequence that is at least 80% identical (e.g., at least 90% or 95% identical) to a HGF amino acid sequence that is naturally produced in an animal, including all allelic variants. In one embodiment, the term refers to isoforms that are known to have cell proliferation activity. Isoforms of HGF include, without limitation, flHGF, dHGF, NK1, NK2, and NK4, e.g., corresponding to SEQ ID NOs: 2-6, and variants thereof (e.g., NK2 variants, SEQ ID NOs: 11-12).
[0055]The term "flHGF" refers to the full length HGF protein of an animal, e.g., a mammal, e.g., amino acids 1-728 (SEQ ID NO: 2) of human HGF.
[0056]The term "dHGF" refers to the deleted variant of HGF protein produced by alternative splicing of the HGF gene in an animal, e.g., a mammal, e.g., human HGF consisting of 723 amino acids (SEQ ID NO: 3) with deletion of five amino acids in the 1st kringle domain of the alpha chain (F, L, P, S and S) from the full length HGF sequence.
[0057]The term "NK1" refers to an isoform of HGF from an animal, e.g., a mammal, e.g., a human, consisting of the N-terminal hairpin loop and kringle1 domains.
[0058]The term "NK2" refers to an isoform of HGF from an animal, e.g., a mammal, e.g., a human, consisting of the N-terminal hairpin loop, kringle1, and kringle2 domains.
[0059]The term "NK4" refers to an isoform of HGF from an animal, e.g., a mammal, e.g., a human, consisting of the N-terminal hairpin loop, kringle1, kringle2, kringle3, and kringle4 domains.
[0060]The structure and function of HGF has been extensively studied and one of skill in the art is aware of the amino acids in the HGF sequence that are important for retaining substantially all of the biological activity of the protein and that are preferably not changed or only conservatively changed in any sequence variant of HGF. See, e.g., Hartmann et al., Proc. Natl. Acad. Sci. USA 89:11574 (1992); Lokker et al., EMBO J. 11:2503 (1992), Zhou et al., Structure 6:109 (1998), Ultsch et al., Structure 6:1383 (1998), Shimizu et al., Biochem. Biophys. Res. Commun. 189:1329 (1992), Yoshiyama et al., Biochem. Biophys. Res. Commun. 175:660 (1991), each herein incorporated by reference in its entirety. For example, it appears that the N-terminal hairpin loop and kringle1 domains are required for cell proliferation activity. Other amino acids that are not critical to biological activity may be deleted and/or substituted more freely. One of skill in the art can prepare variants of HGF isoforms using routine mutagenesis techniques, such as those described in the references cited above, and identify variants retaining substantially all of the biological activity of the HGF isoform.
[0061]An embodiment of the hybrid HGF gene of the present invention comprising the inherent intron is 7113 bp long and has the nucleotide sequence of SEQ ID NO: 7.
[0062]A hybrid HGF gene may comprise a fragment of inherent intron optionally having a small recombinant sequence inserted thereinto between exons 4 and 5 of HGF cDNA. Herein, such a hybrid HGF gene comprising a fragment of inherent intron is designated "HGF-X". Examples of hybrid HGF genes include HGF-X2 (SEQ ID NO: 13), HGF-X3 (SEQ ID NO: 14), HGF-X6 (SEQ ID NO: 8), HGF-X7 (SEQ ID NO: 9) and HGF-X8 (SEQ ID NO: 10).
Administration and Methods of Treatment
[0063]As described above, HGF has various biological functions, and based on these various functions, HGF, a gene encoding HGF, or a variant thereof, may be developed as a therapeutic agent for treating ischemic or liver diseases. In the present invention, an HGF DNA formulation is administered after reconstitution of the lyophilized DNA formulation.
[0064]The term "reconstituted" or "reconstitution" refers to the restoration to the original form, e.g., by rehydration, of a substance previously altered for preservation and storage, e.g., the restoration to a liquid state of a DNA plasmid formulation that has been previously dried and stored. The lyophilized composition of the present invention may be reconstituted in any aqueous solution which produces a stable, mono-dispersed solution suitable for administration. Such aqueous solutions include, but are not limited to: sterile water, TE, PBS, Tris buffer or normal saline.
[0065]The concentration of reconstituted lyophilized DNA in the methods of the current invention is adjusted depending on many factors, including the amount of a formulation to be delivered, the age and weight of the subject, the delivery method and route and the immunogenicity of the antigen being delivered.
[0066]The reconstituted lyophilized DNA formulation of the invention may be administered orally or via parenteral routes such as intravenous, intramuscular, intraendocardial, intramyocardial, intrapericardial, intraventricular, intraarticular, intradermal, intracerebral, intrarenal, intrahepatic, intrasplenic, intralymphatic, subcutaneous, intraabdominal, intratesticular, intraovarian, intrauterine, sternal, intratracheal, intraplueral, intrathoracic, intradural, intraspinal, intramedullary, intramural, intrascorionic and arterial injection or infusion, or topically through rectal, intranasal, inhalational or intraocular administration. In certain embodiments, the method of delivery is intramuscular, intramyocardial, intravenous, intracerebral, or intrarenal.
[0067]It should be understood that the typical daily dose of the reconstituted lyophilized DNA formulation of the present invention ought to be determined in light of various relevant factors including the conditions to be treated, the chosen route of administration, the age, sex and body weight of the individual patient, and the severity of the patient's symptom, and can be administrated in a single dose or in divided dose. Therefore, the daily dose should not be construed as a limitation to the scope of the invention in any way.
[0068]The term "treat," "treating," or "treatment" of an ischemic or liver disease, as used herein, refers to the administration to a subject of a factor, e.g. a HGF, e.g., a hybrid HGF, or variant thereof, in an amount sufficient to result in amelioration of one or more symptoms of the ischemic or liver disease, or prevent advancement of the ischemic or liver disease.
[0069]An "ischemic disease" refers to a disease associated with a deficient supply of blood to a body part (as the heart or brain) that is due to obstruction of the inflow of arterial blood (as by the narrowing of arteries by spasm or disease). Examples of ischemic diseases include coronary artery disease (CAD) and peripheral artery disease (PAD).
[0070]The term "liver disease" applies to many diseases and disorders that cause the liver to function improperly or cease functioning. HGF is a major agent promoting hepatocyte proliferation, and acts in concert with transforming growth factor-alpha and heparin-binding epidermal growth factor during liver regeneration. Additionally, HGF ameliorates hepatic injury via anti-apoptotic effects in animal models of fulminant hepatic failure, and attenuates hepatic fibrosis in animals with liver cirrhosis. Consequently, HGF is considered to not only induce liver regeneration, but also to inhibit disease progression and ameliorate hepatic fibrosis in patients suffering from intractable liver diseases. With respect to the treatment of liver disease, the reconstituted lyophilized DNA formulation of the invention may be administered according to the delivery methods as set forth above. In certain embodiments, the method of delivery in the treatment of liver disease will be intravenous, intraarterial, or intrahepatic.
[0071]In certain aspects of the invention, the reconstituted HGF DNA formulation can comprise two or more isoforms of HGF. The HGF isoforms may be previously lyophilized separately, or in the same DNA formulation. Both of these lyophilized isoforms, after reconstitution, can be administered separately or at the same time, i.e., co-administered; separate reconstituted plasmid DNA formulations for the two or more isoforms of HGF may be administered or co-administered or a single expression plasmid containing genes for two or more isoforms of HGF and capable of expressing the genes for the two or more isoforms of HGF may be administered. For example, the two isoforms flHGF and dHGF may be administered using two separate plasmids. Alternatively, the two separate plasmids containing genes for flHGF and dHGF may be used for co-administration. Finally, a single expression plasmid containing genes for both flHGF and dHGF may be administered. In certain aspects of the invention, the flHGF and dHGF on a single expression plasmid is encoded by the same polynucleotide or by separate polynucleotides.
[0072]There are a number of approaches to include more than one polynucleotide capable of expressing an HGF isoform on a single plasmid. These include, for example, the use of Internal Ribosome Entry Site (IRES) sequences, dual promoters/expression cassettes, and fusion proteins. The two or more isoforms expressed from the same plasmid or on two separate plasmids, as discussed above, are selected from the group consisting of flHGF, dHGF, NK1, NK2, and NK4 or selected from the group consisting of SEQ ID NOs: 2 to 6. The two or more isoforms can also include additional HGF isoforms known to one of ordinary skill in the art.
[0073]In certain aspects of the invention, the plasmid DNA is administered through direct intracellular injection and, more preferably, by the use of a syringe or a catheter. Catheters have been used to introduce recombinant genes in vivo (see, e.g., E. G. Nabel, et al., Proc. Natl. Acad. Sci. USA 89, 5157 (1992); E. G. Nabel, et al., Science 249, 1285 (1990); E. G. Nabel, et al., Science 244, 1342 (1989); E. G. Nabel, et al., J. Clin. Invest. 91, 1822 (1993); G. Plautz, et al., Circ. 83, 578 (1991); E. G. Nabel, et al., Nature (1993) (in press)). Utilization of a catheter provides the ability to deliver the plasmid DNA into the cells which are difficult to access by the use of a syringe.
[0074]The plasmid DNA can be administered through intraarterial or intravenous injection and, more preferably, by the use of a syringe or a catheter. For example, the femoral artery may be used to deliver plasmid DNA to the heart; the portal vein may be used to deliver plasmid DNA to the liver.
[0075]Administration of the plasmid DNA of the invention can also be accomplished by gene transfer into target cells, in situ, to optimize the subsequent delivery of genes in vivo.
[0076]The practice of the present invention will employ, unless otherwise indicated, conventional techniques of cell biology, cell culture, molecular biology (including PCR), vaccinology, microbiology, recombinant DNA, and immunology, which are within the skill of the art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, 2nd Ed., Sambrook et al., ed., Cold Spring Harbor Laboratory Press: (1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); Mullis et al. U.S. Pat. No. 4,683,195; Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); Transcription And Translation (B. D. Hames & S. J. Higgins eds. 1984); Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986); B. Perbal, A Practical Guide To Molecular Cloning (1984); the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.); Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); Methods In Enzymology, Vols. 154 and 155 (Wu et al. eds.), Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987); and in Ausubel et al., Current Protocols in Molecular Biology, John Wiley and Sons, Baltimore, Md. (1989). Each of the references cited in this paragraph is incorporated herein by reference in its entirety.
[0077]The following Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention.
EXAMPLES
Example 1
Preparation of Plasmid
[0078]The plasmid pCK-HGF-X7 (WO 03/078568) which is designed to express hepatocyte growth factor (HGF) protein was used in the experiment.
[0079]E. coli (TOP10, Invitrogen, USA) were transformed with pCK-HGF-X7, and a single colony was isolated. The isolated colony was then cultured in LB media containing 30 μg/mL kanamycin. Plasmid DNA was purified using an EndoFree plasmid Giga kit (Qiagen, USA), and re-suspended in saline containing 0.9% NaCl at a final DNA concentration of 1.0 to 2.0 mg/mL.
Example 2
Lyophilization
[0080]Formulations of pCK-HGF-X7 were prepared in saline containing 0.9% NaCl at a final DNA concentration of 0.5 mg/mL or 1 mg/mL, with sucrose (0.25, 1.1, 5, 10 or 20% w/v) or mannitol (1.2, 4.85 or 10% w/v). Table 1A and 1B show the percentage sucrose and mannitol, respectively, and the corresponding carbohydrate/DNA (w/w) ratios for the tested pCK-HGF-X7 formulations.
TABLE-US-00001 TABLE 1A Percent Sucrose DNA Sucrose Sucrose Sucrose (mg/ml) (%) (mg/ml)) to DNA ratio (w/w) 0.5 0.25 2.5 5 0.5 1.1 11 22 0.5 5 50 100 0.5 10 100 200 0.5 20 200 400 1 0.25 2.5 2.5 1 1.1 11 11 1 5 50 50 1 10 100 100 1 20 200 200
TABLE-US-00002 TABLE 1B Percent Mannitol DNA Mannitol Mannitol Mannitol (mg/ml) (%) (mg/ml)) to DNA ratio (w/w) 0.5 1.2 12 24 0.5 4.85 48.5 97 0.5 10 100 200 1 1.2 12 12 1 4.85 48.5 48.5 1 10 100 100
[0081]The suspended plasmid DNA was then lyophilized with Production-Master Freeze Dryer (C&H Cooling & Heating Systems, Korea). The temperature was lowered to -50° C. for 4 hours at 100 mTorr. Then, the temperature was raised to -40° C. for 12 hours, -30° C. for 6 hours, -20° C. for 6 hours, -10° C. for 6 hours, 0° C. for 6 hours, 10° C. for 6 hours and 30° C. for 24 hours, progressively, at 28˜29 mTorr. The lyophilized plasmid DNA was kept at -20° C. until analyzed.
[0082]The suspended plasmid DNA was also lyophilized with Production-Master Freeze Dryer (C&H Cooling & Heating Systems, Korea). The temperature was lowered to 5° C. for 1 minute, and -50° C. for 2 hours at 100 mTorr. Then, the temperature was raised to -40° C. for 6 hours, -35° C. for 3 hours, -30° C. for 6 hours, -25° C. for 3 hours, -20° C. for 3 hours, -15° C. for 3 hours, -10° C. for 6 hours, -5° C. for 3 hours, 0° C. for 6 hours, and 30° C. for 17 hours, progressively, at 28˜29 mTorr. The lyophilized plasmid DNA was kept at -20° C. until analyzed.
[0083]The suspended plasmid DNA was also lyophilized with Production-Master Freeze Dryer (C&H Cooling & Heating Systems, Korea). The temperature was lowered to 5° C. for 1 minute, -10° C. for 1 minute, -20° C. for 1 minute, -30° C. for 1 minute, and -50° C. for 1 minute at 150 mTorr. The temperature was maintained at -50° C. for another 2 hours at 150 mTorr. Then, the temperature was raised to -45° C. for 6 hours, -40° C. for 3 hours, -35° C. for 6 hours, -30° C. for 3 hours, -25° C. for 6 hours, -20° C. for 3 hours, -15° C. for 6 hours, -10° C. for 3 hours, -5° C. for 6 hours, 0° C. for 12 hours, 10° C. for 3 hours, 20° C. for 6 hours, and 30° C. for 29 hours, progressively, at 30 mTorr. The lyophilized plasmid DNA was kept at -20° C. until analyzed.
[0084]The lyophilized formulations prepared above were analyzed for in vitro gene expression efficiency according to the methods described in Example 3. The in vitro results for these preparations were the same.
Example 3
Effects of Lyophilization on In Vitro Gene Expression Efficiency of Plasmid DNA
[0085]1. Materials and methods
[0086]To assess the effects of the lyophilization on gene expression efficiency of plasmid DNA, the lyophilized plasmid DNA was transfected into 293T cells, and the level of HGF expression was measured. As a control, non-lyophilized plasmid DNA was also transfected.
[0087]Four micrograms of pCK-HGF-X7 in various formulations (as noted above in Example 1) were transfected into 1×106 293T cells using FuGENE6 (Roche Diagnostics, Germany) (n=5). Before transfection, 1 mg of the lyophilized plasmid DNA was reconstituted with 2 ml of water for injection to the final concentration of 0.5 mg/mL.
[0088]Two days after transfection, the culture supernatants were obtained and analyzed for HGF expression using a human HGF ELISA kit (R&D Systems, MN, USA), according to the manufacturer's recommendations. The ELISA results were statistically assessed by Dunnett's multiple comparison test using SPSS program (version 13.0, SPSS. Inc, USA).
2. Results and Discussion
[0089]The results of HGF gene expression are provided in FIG. 1. Contrary to previous reports, lyophilization did not affect the in vitro gene expression efficiency of plasmid DNA. Among various formulations, the HGF level from pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl was significantly higher than that from non-lyophilized pCK-HGF-X7 (p=0.001) (FIG. 1).
[0090]These results indicate that the lyophilization formulation containing 1.1% Sucrose and 0.9% NaCl would be more suitable for pCK-HGF-X7 than a non-lyophilized formulation.
Example 4
Comparative Analysis of In Vivo Gene Expression Between Non-Lyophilized and Lyophilized pCK-HGF-X7
1. Materials and Methods
[0091]Thirteen 5-week old BALB/c mice (males, Charles River) were obtained for each group, and provided with food and water ad libitum. The mice were allowed 7 days of rest before being subjected to the experiment.
[0092]Mice were injected with 100 μg of non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7) or pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7) into the tibialis cranialis, and were sacrificed at day 7 after treatment. The lyophilized plasmid DNA was reconstituted with water to the final concentration of 0.5 mg/mL before injection. To measure the level of HGF protein expression, the injected muscles were collected, and the muscle tissue was lysed with 500 μL of cell lysis buffer (50 mM NaCl, 0.2% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 2% IGEPAL CA-630, 25 mM Tris-HCl, pH7.4, 1 mM phenylmethylsulfonyl fluoride) for 16 hours at 4° C. The lysates were centrifuged at 12,000 rpm for 5 minutes, and the supernatants were harvested and analyzed for HGF expression using a human HGF ELISA kit (R&D Systems).
[0093]The ELISA results were statistically assessed by one way ANOVA and subsequent Tukey's Test using SPSS program (version 13.0).
2. Results and discussion
[0094]An average of 246 ng/mL of HGF protein was produced from the animals administered with pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7), while the animals administered with non-lyophilized pCK-HGF-X7 expressed 76 ng/mL of HGF (FIG. 2). This result indicates that pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl can express HGF protein more efficiently than non-lyophilized pCK-HGF-X7 (p<0.001).
Example 5
Comparative Analysis of Therapeutic Effects on Porcine Ischemic Heart Disease Model Between Non-Lyophilized and Lyophilized pCK-HGF-X7
[0095]1. Materials and methods
(1) Animals
[0096]Eleven Yorkshire pigs (male, 28 to 30 kg, Clinical Research Institute in Seoul National University Hospital) were obtained and provided with food two-times per day and water ad libitum. The pigs were allowed 7 days of rest before being subjected to the experiment. The overall experimental plan is shown in FIG. 3.
(2) Establishment of the Porcine Ischemic Heart Disease Model
[0097]Xylazine (2 mg/kg), ketamine (20 mg/kg), and atropine (0.05 mg/kg) were injected intramuscularly into each pig. Twenty minutes later, a 22-gauge Medicut sheath was inserted into the superficial femoral artery for continuous monitoring of the blood pressure. Thiopental sodium (10 mg/kg) was injected intravenously, and endotracheal intubation was performed via the orotracheal route. Anesthesia was maintained by inhalation of enflurane. During the operation, positive pressure ventilation and an oxygen fraction of 30%˜40% were maintained. Electrocardiograms, oxygen saturation and arterial blood pressure were monitored continuously.
[0098]Left thoracotomy was then performed. After opening the pericardium followed by exploration of the left anterior descending coronary artery (LAD), 2% lidocaine (1 mg/kg) was injected intravenously and the distal one third of the LAD was ligated for 3 minutes, leaving the second diagonal branch as much as possible. Reperfusion (ischemic preconditioning) was performed for 5 minutes using 5-0 polypropylene sutures buttressed with a small piece of Nelaton (4 Fr). After this single ischemic preconditioning, the distal LAD was ligated and ST-segment depression or elevation on the monitored electrocardiogram was confirmed. Additional lidocaine (1 mg/kg) was injected intravenously 15 minutes after the ligation, and the pericardium and thoracotomy wounds were closed. A single 28 Fr chest tube connected to wall suction was removed immediately after enough spontaneous respiration returned, followed by the removal of the endotracheal tube.
[0099]All protocols were approved by the Seoul National University Animal Care and Use Committee.
(3) Intramyocardial Injection of Plasmids
[0100]Twenty eight days after the ligation of the coronary artery, re-thoracotomy was performed. Using 27 gauge insulin injection needles, a total dose of 1 mg of pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl (L-HGF-X7, n=3) or non-lyophilized pCK-HGF-X7 containing 0.9% NaCl (NL-HGF-X7, n=4) was injected into the anterolateral ischemic border zone which lies between the fibrotic infarction area and the grossly normal myocardium along the course of the second diagonal branch. A total of five sites were injected. Each site was injected with 0.2 mg of plasmid DNA and the interval between injection sites was 1.5 cm. The lyophilized plasmid DNA was reconstituted with water to the final concentration of 1 mg/mL before injection. As a control, the identical amount of non-lyophilized pCK containing 0.9% NaCl (n=4) was injected into the anterolateral ischemic border zone. The injection points were marked with suture tags using metal rings.
(4) Myocardial Single Photon Emission Computed Tomography
[0101]Twenty six days after the surgical induction of myocardial infarction, 99mTc-MIBI gated single photon emission computed tomography (SPECT)(Vertex EPIC, ADAC Labs, CA., USA) was performed to set a baseline before plasmid injection. The gated SPECT was repeated 28 days later (on Day 54 after the induction of the myocardial infarction).
[0102]A 20-segment model was chosen for a segmental analysis. Six segments corresponding to the cardiac base were excluded from the analysis because this region could be easily influenced by the diaphragmatic attenuation or some artifacts around the heart; also because the heart base was far away from the sites of the distal coronary ligation and plasmid injection.
[0103]The SPECT images constructed by electrocardiography gating were analyzed by an auto-quantitation program (AutoQUANT, ADAC Labs, CA., USA), which is believed to eliminate the possible bias by any associated technician's manipulation.
[0104]The amount of segmental perfusion was quantified by measuring the uptake of 99mTc-MIBI and calculated as a percentage of the maximum uptake. When the segmental perfusion thus estimated was less than 70%, it was defined as an underperfused segment and used as the target of plasmid delivery. Segments remaining well perfused even after the coronary ligation were also excluded, as they would probably get no benefit from the therapeutic angiogenesis. Wall thickening in the systolic phase was indicated as a percentage of the end diastolic wall thickness on the gated images.
(5) Statistics
[0105]Data are presented as the percent improvement compared to the baseline. All data were analyzed using SPSS (version 13.0). The statistical analysis of the myocardial perfusion and the segmental wall-thickening was performed using paired-samples Student t-test.
2. Results
[0106]Within each treatment group, the changes in the segmental perfusion before and after the plasmid DNA injection were compared. The baseline values for the average of segmental perfusion measured on Day 26 after LAD ligation were 39.0±14.6, 43.4±13.4 and 36.9±16.3% for pCK, NL-HGF-X7 and L-HGF-X7 treatment group, respectively. 99mTc-MIBI gated SPECT conducted on Day 54 showed that the average values of the segmental perfusion in the pCK and NL-HGF-X7 groups were 37.8±13.9% and 44.0±14.5%, respectively, which were not significantly different from the baseline values measured on Day 26 (p=0.320 for pCK and 0.721 for NL-HGF-X7). In contrast, the average value of the segmental perfusion in the L-HGF-X7 treatment group was 41.2±17.6%, showing significant increase over the baseline value (p=0.003). When the magnitude of the percent increase in the segmental perfusion from baseline value was compared between groups, the percent increase of the segmental perfusion in the L-HGF-X7 treatment group was 14.74% higher than that of pCK treatment group (p=0.003), while the NL-HGF-X7 treatment group did not show significant difference from the pCK treatment group (p=0.254) (FIG. 4).
[0107]In each treatment group, the changes in the segmental wall-thickening before and after the DNA administration were also compared. On Day 26, the average values of the segmental wall-thickening were 24.7±16.5, 33.4±15.9 and 16.5±15.9% for pCK, NL-HGF-X7 and L-HGF-X7 treated group, respectively, and there were no significant inter-group differences (p=NS). On Day 54, the average value of segmental wall-thickening for pCK, NL-HGF-X7 and L-HGF-X7 treatment group was 27.9±18.4, 43.1±11.8, and 30.2±10.7%, respectively. When the magnitude of the percent increase in the segmental wall-thickening from baseline value was compared between the treatment groups, the percent increase in the L-HGF-X7 treatment group was 83.54%, which was significantly higher than that of the NL-HGF-X7 group (28.99%) (FIG. 5).
[0108]These results indicate that the intramyocardial administration of the lyophilized formulation (L-HGF-X7) can more efficiently increase the regional blood flow and wall-thickening in the injected ischemic border area of left ventricle compared to the non-lyophilized formulation (NL-HGF-X7). Without wishing to be bound by theory, this is likely due to angiogenic and antifibrotic activities of expressed HGF-X7.
3. Summary
[0109]The segmental perfusion and wall-thickening were significantly increased in the lyophilized pCK-HGF-X7 treated group as compared to those of the non-lyophilized pCK and pCK-HGF-X7 treated groups.
[0110]These results demonstrate that the intramyocardial administration of pCK-HGF-X7 lyophilized with 1.1% sucrose and 0.9% NaCl to the affected pigs could efficiently and stably increase the regional perfusion and the wall-thickening in the ischemic myocardium as compared to non-lyophilized pCK-HGF-X7.
[0111]While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.
Sequence CWU
1
1412187DNAHomo sapiens 1atgtgggtga ccaaactcct gccagccctg ctgctgcagc
atgtcctcct gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga
aaagaagaaa tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag
atccagcact gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat
gtactaggaa taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa
aacaatgcct ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc
atgaatttga cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac
gcagctacaa gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt
ccatgatacc acacgaacac 480agctttttgc cttcgagcta tcggggtaaa gacctacagg
aaaactactg tcgaaatcct 540cgaggggaag aagggggacc ctggtgtttc acaagcaatc
cagaggtacg ctacgaagtc 600tgtgacattc ctcagtgttc agaagttgaa tgcatgacct
gcaatgggga gagttatcga 660ggtctcatgg atcatacaga atcaggcaag atttgtcagc
gctgggatca tcagacacca 720caccggcaca aattcttgcc tgaaagatat cccgacaagg
gctttgatga taattattgc 780cgcaatcccg atggccagcc gaggccatgg tgctatactc
ttgaccctca cacccgctgg 840gagtactgtg caattaaaac atgcgctgac aatactatga
atgacactga tgttcctttg 900gaaacaactg aatgcatcca aggtcaagga gaaggctaca
ggggcactgt caataccatt 960tggaatggaa ttccatgtca gcgttgggat tctcagtatc
ctcacgagca tgacatgact 1020cctgaaaatt tcaagtgcaa ggacctacga gaaaattact
gccgaaatcc agatgggtct 1080gaatcaccct ggtgttttac cactgatcca aacatccgag
ttggctactg ctcccaaatt 1140ccaaactgtg atatgtcaca tggacaagat tgttatcgtg
ggaatggcaa aaattatatg 1200ggcaacttat cccaaacaag atctggacta acatgttcaa
tgtgggacaa gaacatggaa 1260gacttacatc gtcatatctt ctgggaacca gatgcaagta
agctgaatga gaattactgc 1320cgaaatccag atgatgatgc tcatggaccc tggtgctaca
cgggaaatcc actcattcct 1380tgggattatt gccctatttc tcgttgtgaa ggtgatacca
cacctacaat agtcaattta 1440gaccatcccg taatatcttg tgccaaaacg aaacaattgc
gagttgtaaa tgggattcca 1500acacgaacaa acataggatg gatggttagt ttgagataca
gaaataaaca tatctgcgga 1560ggatcattga taaaggagag ttgggttctt actgcacgac
agtgtttccc ttctcgagac 1620ttgaaagatt atgaagcttg gcttggaatt catgatgtcc
acggaagagg agatgagaaa 1680tgcaaacagg ttctcaatgt ttcccagctg gtatatggcc
ctgaaggatc agatctggtt 1740ttaatgaagc ttgccaggcc tgctgtcctg gatgattttg
ttagtacgat tgatttacct 1800aattatggat gcacaattcc tgaaaagacc agttgcagtg
tttatggctg gggctacact 1860ggattgatca actatgatgg cctattacga gtggcacatc
tctatataat gggaaatgag 1920aaatgcagcc agcatcatcg agggaaggtg actctgaatg
agtctgaaat atgtgctggg 1980gctgaaaaga ttggatcagg accatgtgag ggggattatg
gtggcccact tgtttgtgag 2040caacataaaa tgagaatggt tcttggtgtc attgttcctg
gtcgtggatg tgccattcca 2100aatcgtcctg gtatttttgt ccgagtagca tattatgcaa
aatggataca caaaattatt 2160ttaacatata aggtaccaca gtcatag
21872728PRTHomo sapiens 2Met Trp Val Thr Lys Leu
Leu Pro Ala Leu Leu Leu Gln His Val Leu1 5
10 15Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr
Ala Glu Gly Gln 20 25 30 Arg
Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35
40 45Thr Leu Ile Lys Ile Asp Pro Ala Leu
Lys Ile Lys Thr Lys Lys Val 50 55
60Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu65
70 75 80Pro Phe Thr Cys Lys
Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85
90 95Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly
Val Lys Lys Glu Phe 100 105
110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys
115 120 125Ile Ile Gly Lys Gly Arg Ser
Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135
140Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu
His145 150 155 160Ser Phe
Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr
165 170 175Cys Arg Asn Pro Arg Gly Glu
Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185
190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys
Ser Glu 195 200 205Val Glu Cys Met
Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp 210
215 220His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp
His Gln Thr Pro225 230 235
240His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp
245 250 255Asp Asn Tyr Cys Arg
Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260
265 270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala
Ile Lys Thr Cys 275 280 285Ala Asp
Asn Thr Met Asn Asp Thr Asp Val Pro Leu Glu Thr Thr Glu 290
295 300Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly
Thr Val Asn Thr Ile305 310 315
320Trp Asn Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu
325 330 335His Asp Met Thr
Pro Glu Asn Phe Lys Cys Lys Asp Leu Arg Glu Asn 340
345 350 Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro
Trp Cys Phe Thr Thr 355 360 365Asp
Pro Asn Ile Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp 370
375 380Met Ser His Gly Gln Asp Cys Tyr Arg Gly
Asn Gly Lys Asn Tyr Met385 390 395
400Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp
Asp 405 410 415Lys Asn Met
Glu Asp Leu His Arg His Ile Phe Trp Glu Pro Asp Ala 420
425 430 Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn
Pro Asp Asp Asp Ala His 435 440
445Gly Pro Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys 450
455 460Pro Ile Ser Arg Cys Glu Gly Asp
Thr Thr Pro Thr Ile Val Asn Leu465 470
475 480Asp His Pro Val Ile Ser Cys Ala Lys Thr Lys Gln
Leu Arg Val Val 485 490
495Asn Gly Ile Pro Thr Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg
500 505 510 Tyr Arg Asn Lys His Ile
Cys Gly Gly Ser Leu Ile Lys Glu Ser Trp 515 520
525Val Leu Thr Ala Arg Gln Cys Phe Pro Ser Arg Asp Leu Lys
Asp Tyr 530 535 540Glu Ala Trp Leu Gly
Ile His Asp Val His Gly Arg Gly Asp Glu Lys545 550
555 560Cys Lys Gln Val Leu Asn Val Ser Gln Leu
Val Tyr Gly Pro Glu Gly 565 570
575Ser Asp Leu Val Leu Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp
580 585 590 Phe Val Ser Thr Ile
Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu 595
600 605Lys Thr Ser Cys Ser Val Tyr Gly Trp Gly Tyr Thr
Gly Leu Ile Asn 610 615 620Tyr Asp Gly
Leu Leu Arg Val Ala His Leu Tyr Ile Met Gly Asn Glu625
630 635 640Lys Cys Ser Gln His His Arg
Gly Lys Val Thr Leu Asn Glu Ser Glu 645
650 655Ile Cys Ala Gly Ala Glu Lys Ile Gly Ser Gly Pro
Cys Glu Gly Asp 660 665 670
Tyr Gly Gly Pro Leu Val Cys Glu Gln His Lys Met Arg Met Val Leu
675 680 685Gly Val Ile Val Pro Gly Arg
Gly Cys Ala Ile Pro Asn Arg Pro Gly 690 695
700Ile Phe Val Arg Val Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile
Ile705 710 715 720Leu Thr
Tyr Lys Val Pro Gln Ser 7253723PRTHomo sapiens 3Met Trp
Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu1 5
10 15Leu His Leu Leu Leu Leu Pro Ile
Ala Ile Pro Tyr Ala Glu Gly Gln 20 25
30Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys
Thr 35 40 45Thr Leu Ile Lys Ile
Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50 55
60Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys
Gly Leu65 70 75 80Pro
Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys
85 90 95Leu Trp Phe Pro Phe Asn Ser
Met Ser Ser Gly Val Lys Lys Glu Phe 100 105
110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg
Asn Cys 115 120 125Ile Ile Gly Lys
Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys 130
135 140Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile
Pro His Glu His145 150 155
160Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr Cys Arg Asn Pro Arg
165 170 175Gly Glu Glu Gly Gly
Pro Trp Cys Phe Thr Ser Asn Pro Glu Val Arg 180
185 190 Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu Val
Glu Cys Met Thr 195 200 205Cys Asn
Gly Glu Ser Tyr Arg Gly Leu Met Asp His Thr Glu Ser Gly 210
215 220Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro
His Arg His Lys Phe225 230 235
240Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp Asp Asn Tyr Cys Arg
245 250 255Asn Pro Asp Gly
Gln Pro Arg Pro Trp Cys Tyr Thr Leu Asp Pro His 260
265 270 Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys
Ala Asp Asn Thr Met 275 280 285Asn
Asp Thr Asp Val Pro Leu Glu Thr Thr Glu Cys Ile Gln Gly Gln 290
295 300Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr
Ile Trp Asn Gly Ile Pro305 310 315
320Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu His Asp Met Thr
Pro 325 330 335Glu Asn Phe
Lys Cys Lys Asp Leu Arg Glu Asn Tyr Cys Arg Asn Pro 340
345 350 Asp Gly Ser Glu Ser Pro Trp Cys Phe Thr
Thr Asp Pro Asn Ile Arg 355 360
365Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp Met Ser His Gly Gln 370
375 380Asp Cys Tyr Arg Gly Asn Gly Lys
Asn Tyr Met Gly Asn Leu Ser Gln385 390
395 400Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp Lys
Asn Met Glu Asp 405 410
415Leu His Arg His Ile Phe Trp Glu Pro Asp Ala Ser Lys Leu Asn Glu
420 425 430 Asn Tyr Cys Arg Asn Pro
Asp Asp Asp Ala His Gly Pro Trp Cys Tyr 435 440
445Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys Pro Ile Ser
Arg Cys 450 455 460Glu Gly Asp Thr Thr
Pro Thr Ile Val Asn Leu Asp His Pro Val Ile465 470
475 480Ser Cys Ala Lys Thr Lys Gln Leu Arg Val
Val Asn Gly Ile Pro Thr 485 490
495Arg Thr Asn Ile Gly Trp Met Val Ser Leu Arg Tyr Arg Asn Lys His
500 505 510 Ile Cys Gly Gly Ser
Leu Ile Lys Glu Ser Trp Val Leu Thr Ala Arg 515
520 525Gln Cys Phe Pro Ser Arg Asp Leu Lys Asp Tyr Glu
Ala Trp Leu Gly 530 535 540Ile His Asp
Val His Gly Arg Gly Asp Glu Lys Cys Lys Gln Val Leu545
550 555 560Asn Val Ser Gln Leu Val Tyr
Gly Pro Glu Gly Ser Asp Leu Val Leu 565
570 575Met Lys Leu Ala Arg Pro Ala Val Leu Asp Asp Phe
Val Ser Thr Ile 580 585 590
Asp Leu Pro Asn Tyr Gly Cys Thr Ile Pro Glu Lys Thr Ser Cys Ser
595 600 605Val Tyr Gly Trp Gly Tyr Thr
Gly Leu Ile Asn Tyr Asp Gly Leu Leu 610 615
620Arg Val Ala His Leu Tyr Ile Met Gly Asn Glu Lys Cys Ser Gln
His625 630 635 640His Arg
Gly Lys Val Thr Leu Asn Glu Ser Glu Ile Cys Ala Gly Ala
645 650 655Glu Lys Ile Gly Ser Gly Pro
Cys Glu Gly Asp Tyr Gly Gly Pro Leu 660 665
670 Val Cys Glu Gln His Lys Met Arg Met Val Leu Gly Val Ile
Val Pro 675 680 685Gly Arg Gly Cys
Ala Ile Pro Asn Arg Pro Gly Ile Phe Val Arg Val 690
695 700Ala Tyr Tyr Ala Lys Trp Ile His Lys Ile Ile Leu
Thr Tyr Lys Val705 710 715
720Pro Gln Ser4207PRTHomo sapiens 4Met Trp Val Thr Lys Leu Leu Pro Ala
Leu Leu Leu Gln His Val Leu1 5 10
15Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly
Gln 20 25 30Arg Lys Arg Arg
Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35
40 45Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys
Thr Lys Lys Val 50 55 60Asn Thr Ala
Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu65 70
75 80Pro Phe Thr Cys Lys Ala Phe Val
Phe Asp Lys Ala Arg Lys Gln Cys 85 90
95Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys
Glu Phe 100 105 110 Gly His
Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115
120 125Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly
Thr Val Ser Ile Thr Lys 130 135 140Ser
Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His145
150 155 160Ser Phe Leu Pro Ser Ser
Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165
170 175Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp
Cys Phe Thr Ser 180 185 190
Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser 195
200 2055290PRTHomo sapiens 5Met Trp Val Thr
Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val Leu1 5
10 15Leu His Leu Leu Leu Leu Pro Ile Ala Ile
Pro Tyr Ala Glu Gly Gln 20 25
30Arg Lys Arg Arg Asn Thr Ile His Glu Phe Lys Lys Ser Ala Lys Thr
35 40 45Thr Leu Ile Lys Ile Asp Pro Ala
Leu Lys Ile Lys Thr Lys Lys Val 50 55
60Asn Thr Ala Asp Gln Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu65
70 75 80Pro Phe Thr Cys Lys
Ala Phe Val Phe Asp Lys Ala Arg Lys Gln Cys 85
90 95Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly
Val Lys Lys Glu Phe 100 105
110 Gly His Glu Phe Asp Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys
115 120 125Ile Ile Gly Lys Gly Arg Ser
Tyr Lys Gly Thr Val Ser Ile Thr Lys 130 135
140Ser Gly Ile Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu
His145 150 155 160Ser Phe
Leu Pro Ser Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr
165 170 175Cys Arg Asn Pro Arg Gly Glu
Glu Gly Gly Pro Trp Cys Phe Thr Ser 180 185
190 Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys
Ser Glu 195 200 205Val Glu Cys Met
Thr Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp 210
215 220His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp
His Gln Thr Pro225 230 235
240His Arg His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp
245 250 255Asp Asn Tyr Cys Arg
Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260
265 270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala
Ile Lys Thr Cys 275 280 285Glu Thr
2906470PRTHomo sapiens 6Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu
Leu Gln His Val Leu1 5 10
15Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln
20 25 30Arg Lys Arg Arg Asn Thr Ile
His Glu Phe Lys Lys Ser Ala Lys Thr 35 40
45Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys
Val 50 55 60Asn Thr Ala Asp Gln Cys
Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu65 70
75 80Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys
Ala Arg Lys Gln Cys 85 90
95Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe
100 105 110 Gly His Glu Phe Asp Leu
Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115 120
125Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile
Thr Lys 130 135 140Ser Gly Ile Lys Cys
Gln Pro Trp Ser Ser Met Ile Pro His Glu His145 150
155 160Ser Phe Leu Pro Ser Ser Tyr Arg Gly Lys
Asp Leu Gln Glu Asn Tyr 165 170
175Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser
180 185 190 Asn Pro Glu Val Arg
Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu 195
200 205Val Glu Cys Met Thr Cys Asn Gly Glu Ser Tyr Arg
Gly Leu Met Asp 210 215 220His Thr Glu
Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr Pro225
230 235 240His Arg His Lys Phe Leu Pro
Glu Arg Tyr Pro Asp Lys Gly Phe Asp 245
250 255Asp Asn Tyr Cys Arg Asn Pro Asp Gly Gln Pro Arg
Pro Trp Cys Tyr 260 265 270
Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys Thr Cys
275 280 285Ala Asp Asn Thr Met Asn Asp
Thr Asp Val Pro Leu Glu Thr Thr Glu 290 295
300Cys Ile Gln Gly Gln Gly Glu Gly Tyr Arg Gly Thr Val Asn Thr
Ile305 310 315 320Trp Asn
Gly Ile Pro Cys Gln Arg Trp Asp Ser Gln Tyr Pro His Glu
325 330 335His Asp Met Thr Pro Glu Asn
Phe Lys Cys Lys Asp Leu Arg Glu Asn 340 345
350 Tyr Cys Arg Asn Pro Asp Gly Ser Glu Ser Pro Trp Cys Phe
Thr Thr 355 360 365Asp Pro Asn Ile
Arg Val Gly Tyr Cys Ser Gln Ile Pro Asn Cys Asp 370
375 380Met Ser His Gly Gln Asp Cys Tyr Arg Gly Asn Gly
Lys Asn Tyr Met385 390 395
400Gly Asn Leu Ser Gln Thr Arg Ser Gly Leu Thr Cys Ser Met Trp Asp
405 410 415Lys Asn Met Glu Asp
Leu His Arg His Ile Phe Trp Glu Pro Asp Ala 420
425 430 Ser Lys Leu Asn Glu Asn Tyr Cys Arg Asn Pro Asp
Asp Asp Ala His 435 440 445Gly Pro
Trp Cys Tyr Thr Gly Asn Pro Leu Ile Pro Trp Asp Tyr Cys 450
455 460Pro Ile Ser Arg Cys Glu465
47077113DNAArtificial Sequencesynthetic hepatocyte growth factor hybrid
7atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc
60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat
120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa
180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt
240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc
300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa
360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta
420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac
480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc
540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat
600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata
660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg
720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa
780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct
840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat
900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat
960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag
1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca
1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact
1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca
1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac
1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg
1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg
1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg
1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca
1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga
1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac
1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga
1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg
1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca
1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact
1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa
1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag
1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga
2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc
2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct
2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat
2220agatgtttat ggccgagagg atccagtata ttaataaaat ccctttttgt attcaatgag
2280ggaaacacat aattttcatc aattagcagc ttattggaat atctgcatga tggtttaaca
2340cttttaagtg ttgactaaag attaatttta cagaaaatag aaaaagaaat atgtttctgt
2400ctggaggaat gatttattgt tgacccctaa attgaaatat tttactagtg gcttaatgga
2460aagatgatga aagatgatga aattaatgta gaagcttaac tagaaaatca ggtgacctga
2520tatctacatc tgtatccttc attggccacc cagcattcat taatgaatca gatgatggaa
2580tagatcaagt ttcctaggaa cacagtgaat attaaaagaa aacaaaggga gcctagcacc
2640tagaagacct agtttatatt tcaaagtata tttggatgta acccaatttt aaacatttcc
2700tcacttgtct ctcttaaagc cttgccaaca gcaaggacag agaaccaaaa atagtgtata
2760tatgaataaa tgcttattac agaatctgct gactggcaca tgctttgtgt gtaatgggtt
2820ctcataaaca cttgttgaat gaacacacat aagtgaaaga gcatggctag gcttcatccc
2880ttggtcaaat atggggtgct aaagaaaagc aggggaaata cattgggaca ctaacaaaaa
2940aaaacagtta atttaggtaa aagataaaat acaccacaga atgaagaaaa gagatgaccc
3000agactgctct ttaaccttca tgtcctagag aggtttttga tatgaattgc attcagaatt
3060gtggaaagga gcccatcttt tctcttcatt ttgattttat taactccaat gggggaattt
3120tattcgtgtt ttggccatat ctacttttga tttctacatt attctctctt cctttctacc
3180tgtatttgtc ctaataaatt gttgacttat taattcacta cttcctcaca gctttttttt
3240ggctttacaa atccactgga aaggtatatg ggtgtatcac tttgtgtatt tcggtgtgca
3300tgtgtagagg ggacaaaaat cctctctcaa actataaata ttgagtattt gtgtattgaa
3360catttgctat aactactagg tttcttaaat aatcttaata tataaaatga tatagaaaaa
3420gggaaattat agttcgtatt attcatctaa gtgaagagat taaaacccag ggagtaaata
3480aattgtctaa ggactaaggt tgtatactat ttaggtgata gatatggggc aaccgtatgg
3540gttttatgat taacaaataa acttctcacc actctaccat atcaactttt ccataaaaga
3600gagctatagt attctttgct taaataaatt tgattagtgc atgacttctt gaaaacatat
3660aaagcaaaag tcacatttga ttctatcaga aaagtgagta agccatggcc caaacaaaag
3720atgcattaaa atattctgga atgatggagc taaaagtaag aaaaatgact ttttaaaaaa
3780gtttactgtt aggaattgtg aaattatgct gaattttagt tgcattataa tttttgtcag
3840tcatacggtc tgacaacctg tcttatttct atttccccat atgaggaatg ctagttaagt
3900atggatatta actattacta cttagatgca ttgaagttgc ataatatgga taatacttca
3960ctggttccct gaaaatgttt agttagtaat aagtctctta cactatttgt tttgtccaat
4020aatttatatt ttctgaagac ttaactctag aatacactca tgtcaaaatg aaagaatttc
4080attgcaaaat attgcttggt acatgacgca tacctgtatt tgttttgtgt cacaacatga
4140aaaatgatgg tttattagaa gtttcattgg gtaggaaaca catttgaatg gtatttacta
4200agatactaaa atccttggac ttcactctaa ttttagtgcc atttagaact caaggtctca
4260gtaaaagtag aaataaagcc tgttaacaaa acacaagctg aatattaaaa atgtaactgg
4320attttcaaag aaatgtttac tggtattacc tgtagatgta tattctttat tatgatcttt
4380tgtgtaaagt ctggcagaca aatgcaatat ctaattgttg agtccaatat cacaagcagt
4440acaaaagtat aaaaaagact tggccttttc taatgtgtta aaatacttta tgctggtaat
4500aacactaaga gtagggcact agaaatttta agtgaagata atgtgttgca gttactgcac
4560tcaatggctt actattataa accaaaactg ggatcactaa gctccagtca gtcaaaatga
4620tcaaaattat tgaagagaat aagcaattct gttctttatt aggacacagt agatacagac
4680tacaaagtgg agtgtgctta ataagaggta gcatttgtta agtgtcaatt actctattat
4740cccttggagc ttctcaaaat aaccatataa ggtgtaagat gttaaaggtt atggttacac
4800tcagtgcaca ggtaagctaa taggctgaga gaagctaaat tacttactgg ggtctcacag
4860taagaaagtg agctgaagtt tcagcccaga tttaactgga ttctgggctc tttattcatg
4920ttacttcatg aatctgtttc tcaattgtgc agaaaaaagg gggctattta taagaaaagc
4980aataaacaaa caagtaatga tctcaaataa gtaatgcaag aaatagtgag atttcaaaat
5040cagtggcagc gatttctcag ttctgtccta agtggccttg ctcaatcacc tgctatcttt
5100tagtggagct ttgaaattat gtttcagaca acttcgattc agttctagaa tgtttgactc
5160agcaaattca caggctcatc tttctaactt gatggtgaat atggaaattc agctaaatgg
5220atgttaataa aattcaaacg ttttaaggac agatgaaaat gacagaattt taaggtaaaa
5280tatatgaagg aatataagat aaaggatttt tctaccttca gcaaaaacat acccactaat
5340tagtaaaatt aataggcaaa aaaaagttgc atgctcttat actgtaatga ttatcatttt
5400aaaactagct ttttgccttc gagctatcgg ggtaaagacc tacaggaaaa ctactgtcga
5460aatcctcgag gggaagaagg gggaccctgg tgtttcacaa gcaatccaga ggtacgctac
5520gaagtctgtg acattcctca gtgttcagaa gttgaatgca tgacctgcaa tggggagagt
5580tatcgaggtc tcatggatca tacagaatca ggcaagattt gtcagcgctg ggatcatcag
5640acaccacacc ggcacaaatt cttgcctgaa agatatcccg acaagggctt tgatgataat
5700tattgccgca atcccgatgg ccagccgagg ccatggtgct atactcttga ccctcacacc
5760cgctgggagt actgtgcaat taaaacatgc gctgacaata ctatgaatga cactgatgtt
5820cctttggaaa caactgaatg catccaaggt caaggagaag gctacagggg cactgtcaat
5880accatttgga atggaattcc atgtcagcgt tgggattctc agtatcctca cgagcatgac
5940atgactcctg aaaatttcaa gtgcaaggac ctacgagaaa attactgccg aaatccagat
6000gggtctgaat caccctggtg ttttaccact gatccaaaca tccgagttgg ctactgctcc
6060caaattccaa actgtgatat gtcacatgga caagattgtt atcgtgggaa tggcaaaaat
6120tatatgggca acttatccca aacaagatct ggactaacat gttcaatgtg ggacaagaac
6180atggaagact tacatcgtca tatcttctgg gaaccagatg caagtaagct gaatgagaat
6240tactgccgaa atccagatga tgatgctcat ggaccctggt gctacacggg aaatccactc
6300attccttggg attattgccc tatttctcgt tgtgaaggtg ataccacacc tacaatagtc
6360aatttagacc atcccgtaat atcttgtgcc aaaacgaaac aattgcgagt tgtaaatggg
6420attccaacac gaacaaacat aggatggatg gttagtttga gatacagaaa taaacatatc
6480tgcggaggat cattgataaa ggagagttgg gttcttactg cacgacagtg tttcccttct
6540cgagacttga aagattatga agcttggctt ggaattcatg atgtccacgg aagaggagat
6600gagaaatgca aacaggttct caatgtttcc cagctggtat atggccctga aggatcagat
6660ctggttttaa tgaagcttgc caggcctgct gtcctggatg attttgttag tacgattgat
6720ttacctaatt atggatgcac aattcctgaa aagaccagtt gcagtgttta tggctggggc
6780tacactggat tgatcaacta tgatggccta ttacgagtgg cacatctcta tataatggga
6840aatgagaaat gcagccagca tcatcgaggg aaggtgactc tgaatgagtc tgaaatatgt
6900gctggggctg aaaagattgg atcaggacca tgtgaggggg attatggtgg cccacttgtt
6960tgtgagcaac ataaaatgag aatggttctt ggtgtcattg ttcctggtcg tggatgtgcc
7020attccaaatc gtcctggtat ttttgtccga gtagcatatt atgcaaaatg gatacacaaa
7080attattttaa catataaggt accacagtca tag
711384679DNAArtificial SequenceSynthetic HGF-X6 gene 8atgtgggtga
ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca
tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa
aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag
tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt
gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca
tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact
acattagaaa ctgcatcatc ggtaaaggac gcagctacaa gggaacagta 420tctatcacta
agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac
agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt
ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg
caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa
atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga
tcccttcctt tctacctgta tttgtcctaa taaattgttg acttattaat 780tcactacttc
ctcacagctt ttttttggct ttacaaatcc actggaaagg tatatgggtg 840tatcactttg
tgtatttcgg tgtgcatgtg tagaggggac aaaaatcctc tctcaaacta 900taaatattga
gtatttgtgt attgaacatt tgctataact actaggtttc ttaaataatc 960ttaatatata
aaatgatata gaaaaaggga aattatagtt cgtattattc atctaagtga 1020agagattaaa
acccagggag taaataaatt gtctaaggac taaggttgta tactatttag 1080gtgatagata
tggggcaacc gtatgggttt tatgattaac aaataaactt ctcaccactc 1140taccatatca
acttttccat aaaagagagc tatagtattc tttgcttaaa taaatttgat 1200tagtgcatga
cttcttgaaa acatataaag caaaagtcac atttgattct atcagaaaag 1260tgagtaagcc
atggcccaaa caaaagatgc attaaaatat tctggaatga tggagctaaa 1320agtaagaaaa
atgacttttt aaaaaagttt actgttagga attgtgaaat tatgctgaat 1380tttagttgca
ttataatttt tgtcagtcat acggtctgac aacctgtctt atttctattt 1440ccccatatga
ggaatgctag ttaagtatgg atattaacta ttactactta gatgcattga 1500agttgcataa
tatggataat acttcactgg ttccctgaaa atgtttagtt agtaataagt 1560ctcttacact
atttgttttg tccaataatt tatattttct gaagacttaa ctctagaata 1620cactcatgtc
aaaatgaaag aatttcattg caaaatattg cttggtacat gacgcatacc 1680tgtatttgtt
ttgtgtcaca acatgaaaaa tgatggttta ttagaagttt cattgggtag 1740gaaacacatt
tgaatggtat ttactaagat actaaaatcc ttggacttca ctctaatttt 1800agtgccattt
agaactcaag gtctcagtaa aagtagaaat aaagcctgtt aacaaaacac 1860aagctgaata
ttaaaaatgt aactggattt tcaaagaaat gtttactggt attacctgta 1920gatgtatatt
ctttattatg atcttttgtg taaagtctgg cagacaaatg caatatctaa 1980ttgttgagtc
caatatcaca agcagtacaa aagtataaaa aagacttggc cttttctaat 2040gtgttaaaat
actttatgct ggtaataaca ctaagagtag ggcactagaa attttaagtg 2100aagataatgt
gttgcagtta ctgcactcaa tggcttacta ttataaacca aaactgggat 2160cactaagctc
cagtcagtca aaatgatcaa aattattgaa gagaataagc aattctgttc 2220tttattagga
cacagtagat acagactaca aagtggagtg tgcttaataa gaggtagcat 2280ttgttaagtg
tcaattactc tattatccct tggagcttct caaaataacc atataaggtg 2340taagatgtta
aaggttatgg ttacactcag tgcacaggta agctaatagg ctgagagaag 2400ctaaattact
tactggggtc tcacagtaag aaagtgagct gaagtttcag cccagattta 2460actggattct
gggctcttta ttcatgttac ttcatgaatc tgtttctcaa ttgtgcagaa 2520aaaagggggc
tatttataag aaaagcaata aacaaacaag taatgatctc aaataagtaa 2580tgcaagaaat
agtgagattt caaaatcagt ggcagcgatt tctcagttct gtcctaagtg 2640gccttgctca
atcacctgct atcttttagt ggagctttga aattatgttt cagacaactt 2700cgattcagtt
ctagaatgtt tgactcagca aattcacagg ctcatctttc taacttgatg 2760gtgaatatgg
aaattcagct aaatggatgt taataaaatt caaacgtttt aaggacagat 2820gaaaatgaca
gaattttaag gtaaaatata tgaaggaata taagataaag gatttttcta 2880ccttcagcaa
aaacataccc actaattagt aaaattaata ggcaaaaaaa agttgcatgc 2940tcttatactg
taatgattat cattttaaaa ctagcttttt gccttcgagc tatcggggta 3000aagacctaca
ggaaaactac tgtcgaaatc ctcgagggga agaaggggga ccctggtgtt 3060tcacaagcaa
tccagaggta cgctacgaag tctgtgacat tcctcagtgt tcagaagttg 3120aatgcatgac
ctgcaatggg gagagttatc gaggtctcat ggatcataca gaatcaggca 3180agatttgtca
gcgctgggat catcagacac cacaccggca caaattcttg cctgaaagat 3240atcccgacaa
gggctttgat gataattatt gccgcaatcc cgatggccag ccgaggccat 3300ggtgctatac
tcttgaccct cacacccgct gggagtactg tgcaattaaa acatgcgctg 3360acaatactat
gaatgacact gatgttcctt tggaaacaac tgaatgcatc caaggtcaag 3420gagaaggcta
caggggcact gtcaatacca tttggaatgg aattccatgt cagcgttggg 3480attctcagta
tcctcacgag catgacatga ctcctgaaaa tttcaagtgc aaggacctac 3540gagaaaatta
ctgccgaaat ccagatgggt ctgaatcacc ctggtgtttt accactgatc 3600caaacatccg
agttggctac tgctcccaaa ttccaaactg tgatatgtca catggacaag 3660attgttatcg
tgggaatggc aaaaattata tgggcaactt atcccaaaca agatctggac 3720taacatgttc
aatgtgggac aagaacatgg aagacttaca tcgtcatatc ttctgggaac 3780cagatgcaag
taagctgaat gagaattact gccgaaatcc agatgatgat gctcatggac 3840cctggtgcta
cacgggaaat ccactcattc cttgggatta ttgccctatt tctcgttgtg 3900aaggtgatac
cacacctaca atagtcaatt tagaccatcc cgtaatatct tgtgccaaaa 3960cgaaacaatt
gcgagttgta aatgggattc caacacgaac aaacatagga tggatggtta 4020gtttgagata
cagaaataaa catatctgcg gaggatcatt gataaaggag agttgggttc 4080ttactgcacg
acagtgtttc ccttctcgag acttgaaaga ttatgaagct tggcttggaa 4140ttcatgatgt
ccacggaaga ggagatgaga aatgcaaaca ggttctcaat gtttcccagc 4200tggtatatgg
ccctgaagga tcagatctgg ttttaatgaa gcttgccagg cctgctgtcc 4260tggatgattt
tgttagtacg attgatttac ctaattatgg atgcacaatt cctgaaaaga 4320ccagttgcag
tgtttatggc tggggctaca ctggattgat caactatgat ggcctattac 4380gagtggcaca
tctctatata atgggaaatg agaaatgcag ccagcatcat cgagggaagg 4440tgactctgaa
tgagtctgaa atatgtgctg gggctgaaaa gattggatca ggaccatgtg 4500agggggatta
tggtggccca cttgtttgtg agcaacataa aatgagaatg gttcttggtg 4560tcattgttcc
tggtcgtgga tgtgccattc caaatcgtcc tggtattttt gtccgagtag 4620catattatgc
aaaatggata cacaaaatta ttttaacata taaggtacca cagtcatag
467993679DNAArtificial SequenceSynthetic HGF-X7 gene 9atgtgggtga
ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca
tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa
aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag
tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt
gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca
tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact
acattagaaa ctgcatcatc ggtaaaggac gcagctacaa gggaacagta 420tctatcacta
agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac
agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt
ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg
caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa
atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga
tcctgggtag gaaacacatt tgaatggtat ttactaagat actaaaatcc 780ttggacttca
ctctaatttt agtgccattt agaactcaag gtctcagtaa aagtagaaat 840aaagcctgtt
aacaaaacac aagctgaata ttaaaaatgt aactggattt tcaaagaaat 900gtttactggt
attacctgta gatgtatatt ctttattatg atcttttgtg taaagtctgg 960cagacaaatg
caatatctaa ttgttgagtc caatatcaca agcagtacaa aagtataaaa 1020aagacttggc
cttttctaat gtgttaaaat actttatgct ggtaataaca ctaagagtag 1080ggcactagaa
attttaagtg aagataatgt gttgcagtta ctgcactcaa tggcttacta 1140ttataaacca
aaactgggat cactaagctc cagtcagtca aaatgatcaa aattattgaa 1200gagaataagc
aattctgttc tttattagga cacagtagat acagactaca aagtggagtg 1260tgcttaataa
gaggtagcat ttgttaagtg tcaattactc tattatccct tggagcttct 1320caaaataacc
atataaggtg taagatgtta aaggttatgg ttacactcag tgcacaggta 1380agctaatagg
ctgagagaag ctaaattact tactggggtc tcacagtaag aaagtgagct 1440gaagtttcag
cccagattta actggattct gggctcttta ttcatgttac ttcatgaatc 1500tgtttctcaa
ttgtgcagaa aaaagggggc tatttataag aaaagcaata aacaaacaag 1560taatgatctc
aaataagtaa tgcaagaaat agtgagattt caaaatcagt ggcagcgatt 1620tctcagttct
gtcctaagtg gccttgctca atcacctgct atcttttagt ggagctttga 1680aattatgttt
cagacaactt cgattcagtt ctagaatgtt tgactcagca aattcacagg 1740ctcatctttc
taacttgatg gtgaatatgg aaattcagct aaatggatgt taataaaatt 1800caaacgtttt
aaggacagat gaaaatgaca gaattttaag gtaaaatata tgaaggaata 1860taagataaag
gatttttcta ccttcagcaa aaacataccc actaattagt aaaattaata 1920ggcaaaaaaa
agttgcatgc tcttatactg taatgattat cattttaaaa ctagcttttt 1980gccttcgagc
tatcggggta aagacctaca ggaaaactac tgtcgaaatc ctcgagggga 2040agaaggggga
ccctggtgtt tcacaagcaa tccagaggta cgctacgaag tctgtgacat 2100tcctcagtgt
tcagaagttg aatgcatgac ctgcaatggg gagagttatc gaggtctcat 2160ggatcataca
gaatcaggca agatttgtca gcgctgggat catcagacac cacaccggca 2220caaattcttg
cctgaaagat atcccgacaa gggctttgat gataattatt gccgcaatcc 2280cgatggccag
ccgaggccat ggtgctatac tcttgaccct cacacccgct gggagtactg 2340tgcaattaaa
acatgcgctg acaatactat gaatgacact gatgttcctt tggaaacaac 2400tgaatgcatc
caaggtcaag gagaaggcta caggggcact gtcaatacca tttggaatgg 2460aattccatgt
cagcgttggg attctcagta tcctcacgag catgacatga ctcctgaaaa 2520tttcaagtgc
aaggacctac gagaaaatta ctgccgaaat ccagatgggt ctgaatcacc 2580ctggtgtttt
accactgatc caaacatccg agttggctac tgctcccaaa ttccaaactg 2640tgatatgtca
catggacaag attgttatcg tgggaatggc aaaaattata tgggcaactt 2700atcccaaaca
agatctggac taacatgttc aatgtgggac aagaacatgg aagacttaca 2760tcgtcatatc
ttctgggaac cagatgcaag taagctgaat gagaattact gccgaaatcc 2820agatgatgat
gctcatggac cctggtgcta cacgggaaat ccactcattc cttgggatta 2880ttgccctatt
tctcgttgtg aaggtgatac cacacctaca atagtcaatt tagaccatcc 2940cgtaatatct
tgtgccaaaa cgaaacaatt gcgagttgta aatgggattc caacacgaac 3000aaacatagga
tggatggtta gtttgagata cagaaataaa catatctgcg gaggatcatt 3060gataaaggag
agttgggttc ttactgcacg acagtgtttc ccttctcgag acttgaaaga 3120ttatgaagct
tggcttggaa ttcatgatgt ccacggaaga ggagatgaga aatgcaaaca 3180ggttctcaat
gtttcccagc tggtatatgg ccctgaagga tcagatctgg ttttaatgaa 3240gcttgccagg
cctgctgtcc tggatgattt tgttagtacg attgatttac ctaattatgg 3300atgcacaatt
cctgaaaaga ccagttgcag tgtttatggc tggggctaca ctggattgat 3360caactatgat
ggcctattac gagtggcaca tctctatata atgggaaatg agaaatgcag 3420ccagcatcat
cgagggaagg tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa 3480gattggatca
ggaccatgtg agggggatta tggtggccca cttgtttgtg agcaacataa 3540aatgagaatg
gttcttggtg tcattgttcc tggtcgtgga tgtgccattc caaatcgtcc 3600tggtattttt
gtccgagtag catattatgc aaaatggata cacaaaatta ttttaacata 3660taaggtacca
cagtcatag
3679102729DNAArtificial SequenceSynthetic HGF-X8 gene 10atgtgggtga
ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60ctgctcccca
tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120gaattcaaaa
aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180accaaaaaag
tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt 240ccattcactt
gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc 300ttcaatagca
tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa 360aacaaagact
acattagaaa ctgcatcatc ggtaaaggac gcagctacaa gggaacagta 420tctatcacta
agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480aggtaagaac
agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc 540tcatattagt
ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600tgtattacgg
caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660tgttaataaa
atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg 720tatttgtgga
tccttatgtt tcagacaact tcgattcagt tctagaatgt ttgactcagc 780aaattcacag
gctcatcttt ctaacttgat ggtgaatatg gaaattcagc taaatggatg 840ttaataaaat
tcaaacgttt taaggacaga tgaaaatgac agaattttaa ggtaaaatat 900atgaaggaat
ataagataaa ggatttttct accttcagca aaaacatacc cactaattag 960taaaattaat
aggcaaaaaa aagttgcatg ctcttatact gtaatgatta tcattttaaa 1020actagctttt
tgccttcgag ctatcggggt aaagacctac aggaaaacta ctgtcgaaat 1080cctcgagggg
aagaaggggg accctggtgt ttcacaagca atccagaggt acgctacgaa 1140gtctgtgaca
ttcctcagtg ttcagaagtt gaatgcatga cctgcaatgg ggagagttat 1200cgaggtctca
tggatcatac agaatcaggc aagatttgtc agcgctggga tcatcagaca 1260ccacaccggc
acaaattctt gcctgaaaga tatcccgaca agggctttga tgataattat 1320tgccgcaatc
ccgatggcca gccgaggcca tggtgctata ctcttgaccc tcacacccgc 1380tgggagtact
gtgcaattaa aacatgcgct gacaatacta tgaatgacac tgatgttcct 1440ttggaaacaa
ctgaatgcat ccaaggtcaa ggagaaggct acaggggcac tgtcaatacc 1500atttggaatg
gaattccatg tcagcgttgg gattctcagt atcctcacga gcatgacatg 1560actcctgaaa
atttcaagtg caaggaccta cgagaaaatt actgccgaaa tccagatggt 1620ctgaatcacc
ctggtgtttt accactgatc caaacatccg agttggctac tgctcccaaa 1680ttccaaactg
tgatatgtca catggacaag attgttatcg tgggaatggc aaaaattata 1740tgggcaactt
atcccaaaca agatctggac taacatgttc aatgtgggac aagaacatgg 1800aagacttaca
tcgtcatatc ttctgggaac cagatgcaag taagctgaat gagaattact 1860gccgaaatcc
agatgatgat gctcatggac cctggtgcta cacgggaaat ccactcattc 1920cttgggatta
ttgccctatt tctcgttgtg aaggtgatac cacacctaca atagtcaatt 1980tagaccatcc
cgtaatatct tgtgccaaaa cgaaacaatt gcgagttgta aatgggattc 2040caacacgaac
aaacatagga tggatggtta gtttgagata cagaaataaa catatctgcg 2100gaggatcatt
gataaaggag agttgggttc ttactgcacg acagtgtttc ccttctcgag 2160acttgaaaga
ttatgaagct tggcttggaa ttcatgatgt ccacggaaga ggagatgaga 2220aatgcaaaca
ggttctcaat gtttcccagc tggtatatgg ccctgaagga tcagatctgg 2280ttttaatgaa
gcttgccagg cctgctgtcc tggatgattt tgttagtacg attgatttac 2340ctaattatgg
atgcacaatt cctgaaaaga ccagttgcag tgtttatggc tggggctaca 2400ctggattgat
caactatgat ggcctattac gagtggcaca tctctatata atgggaaatg 2460agaaatgcag
ccagcatcat cgagggaagg tgactctgaa tgagtctgaa atatgtgctg 2520gggctgaaaa
gattggatca ggaccatgtg agggggatta tggtggccca cttgtttgtg 2580agcaacataa
aatgagaatg gttcttggtg tcattgttcc tggtcgtgga tgtgccattc 2640caaatcgtcc
tggtattttt gtccgagtag catattatgc aaaatggata cacaaaatta 2700ttttaacata
taaggtacca cagtcatag 272911285PRTHomo
sapiens 11Met Trp Val Thr Lys Leu Leu Pro Ala Leu Leu Leu Gln His Val
Leu1 5 10 15Leu His Leu
Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln 20
25 30Arg Lys Arg Arg Asn Thr Ile His Glu Phe
Lys Lys Ser Ala Lys Thr 35 40
45Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys Lys Val 50
55 60Asn Thr Ala Asp Gln Cys Ala Asn Arg
Cys Thr Arg Asn Lys Gly Leu65 70 75
80Pro Phe Thr Cys Lys Ala Phe Val Phe Asp Lys Ala Arg Lys
Gln Cys 85 90 95Leu Trp
Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe 100
105 110 Gly His Glu Phe Asp Leu Tyr Glu Asn
Lys Asp Tyr Ile Arg Asn Cys 115 120
125Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val Ser Ile Thr Lys
130 135 140Ser Gly Ile Lys Cys Gln Pro
Trp Ser Ser Met Ile Pro His Glu His145 150
155 160Ser Tyr Arg Gly Lys Asp Leu Gln Glu Asn Tyr Cys
Arg Asn Pro Arg 165 170
175Gly Glu Glu Gly Gly Pro Trp Cys Phe Thr Ser Asn Pro Glu Val Arg
180 185 190 Tyr Glu Val Cys Asp Ile
Pro Gln Cys Ser Glu Val Glu Cys Met Thr 195 200
205Cys Asn Gly Glu Ser Tyr Arg Gly Leu Met Asp His Thr Glu
Ser Gly 210 215 220Lys Ile Cys Gln Arg
Trp Asp His Gln Thr Pro His Arg His Lys Phe225 230
235 240Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe
Asp Asp Asn Tyr Cys Arg 245 250
255Asn Pro Asp Gly Gln Pro Arg Pro Trp Cys Tyr Thr Leu Asp Pro His
260 265 270 Thr Arg Trp Glu Tyr
Cys Ala Ile Lys Thr Cys Glu Thr 275 280
28512296PRTHomo sapiens 12Met Trp Val Thr Lys Leu Leu Pro Ala Leu
Leu Leu Gln His Val Leu1 5 10
15Leu His Leu Leu Leu Leu Pro Ile Ala Ile Pro Tyr Ala Glu Gly Gln
20 25 30Arg Lys Arg Arg Asn Thr
Ile His Glu Phe Lys Lys Ser Ala Lys Thr 35 40
45Thr Leu Ile Lys Ile Asp Pro Ala Leu Lys Ile Lys Thr Lys
Lys Val 50 55 60Asn Thr Ala Asp Gln
Cys Ala Asn Arg Cys Thr Arg Asn Lys Gly Leu65 70
75 80Pro Phe Thr Cys Lys Ala Phe Val Phe Asp
Lys Ala Arg Lys Gln Cys 85 90
95Leu Trp Phe Pro Phe Asn Ser Met Ser Ser Gly Val Lys Lys Glu Phe
100 105 110 Gly His Glu Phe Asp
Leu Tyr Glu Asn Lys Asp Tyr Ile Arg Asn Cys 115
120 125Ile Ile Gly Lys Gly Arg Ser Tyr Lys Gly Thr Val
Ser Ile Thr Lys 130 135 140Ser Gly Ile
Lys Cys Gln Pro Trp Ser Ser Met Ile Pro His Glu His145
150 155 160Ser Phe Leu Pro Ser Ser Tyr
Arg Gly Lys Asp Leu Gln Glu Asn Tyr 165
170 175Cys Arg Asn Pro Arg Gly Glu Glu Gly Gly Pro Trp
Cys Phe Thr Ser 180 185 190
Asn Pro Glu Val Arg Tyr Glu Val Cys Asp Ile Pro Gln Cys Ser Glu
195 200 205Val Glu Cys Met Thr Cys Asn
Gly Glu Ser Tyr Arg Gly Leu Met Asp 210 215
220His Thr Glu Ser Gly Lys Ile Cys Gln Arg Trp Asp His Gln Thr
Pro225 230 235 240His Arg
His Lys Phe Leu Pro Glu Arg Tyr Pro Asp Lys Gly Phe Asp
245 250 255Asp Asn Tyr Cys Arg Asn Pro
Asp Gly Gln Pro Arg Pro Trp Cys Tyr 260 265
270 Thr Leu Asp Pro His Thr Arg Trp Glu Tyr Cys Ala Ile Lys
Asn Met 275 280 285Arg Asp Ile Thr
Trp Ala Leu Asn 290 295136190DNAArtificial
SequenceSynthetic Hepatocyte Growth Factor Hybrid (HGF)-X2
13atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc
60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat
120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa
180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa taaaggactt
240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct ctggttcccc
300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga cctctatgaa
360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa gggaacagta
420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac
480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagtc
540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat
600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata
660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcgg
720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg tctttgagaa
780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag atgagaatct
840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc acattaaaat
900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga acaattaaat
960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat gattccaaag
1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agcttttcca
1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca gatgggtact
1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt ttaatcatca
1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct tatttcacac
1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag taatgcattg
1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct catttacttg
1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat gacaaaactg
1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt gacatggcca
1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt cagggcatga
1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg tggtgatgac
1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga
1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgttg
1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag taagtgtcca
1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact
1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa
1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg catagtgaag
1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa tgacatttga
2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag gtcttatttc
2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct
2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatat
2220agatgtttat ggccgagagg atcccttcct ttctacctgt atttgtccta ataaattgtt
2280gacttattaa ttcactactt cctcacagct tttttttggc tttacaaatc cactggaaag
2340gtatatgggt gtatcacttt gtgtatttcg gtgtgcatgt gtagagggga caaaaatcct
2400ctctcaaact ataaatattg agtatttgtg tattgaacat ttgctataac tactaggttt
2460cttaaataat cttaatatat aaaatgatat agaaaaaggg aaattatagt tcgtattatt
2520catctaagtg aagagattaa aacccaggga gtaaataaat tgtctaagga ctaaggttgt
2580atactattta ggtgatagat atggggcaac cgtatgggtt ttatgattaa caaataaact
2640tctcaccact ctaccatatc aacttttcca taaaagagag ctatagtatt ctttgcttaa
2700ataaatttga ttagtgcatg acttcttgaa aacatataaa gcaaaagtca catttgattc
2760tatcagaaaa gtgagtaagc catggcccaa acaaaagatg cattaaaata ttctggaatg
2820atggagctaa aagtaagaaa aatgactttt taaaaaagtt tactgttagg aattgtgaaa
2880ttatgctgaa ttttagttgc attataattt ttgtcagtca tacggtctga caacctgtct
2940tatttctatt tccccatatg aggaatgcta gttaagtatg gatattaact attactactt
3000agatgcattg aagttgcata atatggataa tacttcactg gttccctgaa aatgtttagt
3060tagtaataag tctcttacac tatttgtttt gtccaataat ttatattttc tgaagactta
3120actctagaat acactcatgt caaaatgaaa gaatttcatt gcaaaatatt gcttggtaca
3180tgacgcatac ctgtatttgt tttgtgtcac aacatgaaaa atgatggttt attagaagtt
3240tcattgggta ggaaacacat ttgaatggta tttactaaga tactaaaatc cttggacttc
3300actctaattt tagtgccatt tagaactcaa ggtctcagta aaagtagaaa taaagcctgt
3360taacaaaaca caaactgaat attaaaaatg taactggatt ttcaaagaaa tgtttactgg
3420tattacctgt agatgtatat tctttattat gatcttttgt gtaaagtctg gcagacaaat
3480gcaatatcta attgttgagt ccaatatcac aagcagtaca aaagtataaa aaagacttgg
3540ccttttctaa tgtgttaaaa tactttatgc tggtaataac actaagagta gggcactaga
3600aattttaagt gaagataatg tgttgcagtt actgcactca atggcttact attataaacc
3660aaaactggga tcactaagct ccagtcagtc aaaatgatca aaattattga agagaataag
3720caattctgtt ctttattagg acacagtaga tacagactac aaagtggagt gtgcttaata
3780agaggtagca tttgttaagt gtcaattact ctattatccc ttggagcttc tcaaaataac
3840catataaggt gtaagatgtt aaaggttatg gttacactca gtgcacaggt aagctaatag
3900gctgagagaa gctaaattac ttactggggt ctcacagtaa gaaagtgagc tgaagtttca
3960gcccagattt aactggattc tgggctcttt attcatgtta cttcatgaat ctgtttctca
4020attgtgcaga aaaaaggggg ctatttataa gaaaagcaat aaacaaacaa gtaatgatct
4080caaataagta atgcaagaaa tagtgagatt tcaaaatcag tggcagcgat ttctcagttc
4140tgtcctaagt ggccttgctc aatcacctgc tatcttttag tggagctttg aaattatgtt
4200tcagacaact tcgattcagt tctagaatgt ttgactcagc aaattcacag gctcatcttt
4260ctaacttgat ggtgaatatg gaaattcagc taaatggatg ttaataaaat tcaaacgttt
4320taaggacaga tggaaatgac agaattttaa ggtaaaatat atgaaggaat ataagataaa
4380ggatttttct accttcagca aaaacatacc cactaattag taaaattaat aggcgaaaaa
4440aagttgcatg ctcttatact gtaatgatta tcattttaaa actagctttt tgccttcgag
4500ctatcggggt aaagacctac aggaaaacta ctgtcgaaat cctcgagggg aagaaggggg
4560accctggtgt ttcacaagca atccagaggt acgctacgaa gtctgtgaca ttcctcagtg
4620ttcagaagtt gaatgcatga cctgcaatgg ggagagttat cgaggtctca tggatcatac
4680agaatcaggc aagatttgtc agcgctggga tcatcagaca ccacaccggc acaaattctt
4740gcctgaaaga tatcccgaca agggctttga tgataattat tgccgcaatc ccgatggcca
4800gccgaggcca tggtgctata ctcttgaccc tcacacccgc tgggagtact gtgcaattaa
4860aacatgcgct gacaatacta tgaatgacac tgatgttcct ttggaaacaa ctgaatgcat
4920ccaaggtcaa ggagaaggct acaggggcac tgtcaatacc atttggaatg gaattccatg
4980tcagcgttgg gattctcagt atcctcacga gcatgacatg actcctgaaa atttcaagtg
5040caaggaccta cgagaaaatt actgccgaaa tccagatggg tctgaatcac cctggtgttt
5100taccactgat ccaaacatcc gagttggcta ctgctcccaa attccaaact gtgatatgtc
5160acatggacaa gattgttatc gtgggaatgg caaaaattat atgggcaact tatcccaaac
5220aagatctgga ctaacatgtt caatgtggga caagaacatg gaagacttac atcgtcatat
5280cttctgggaa ccagatgcaa gtaagctgaa tgagaattac tgccgaaatc cagatgatga
5340tgctcatgga ccctggtgct acacgggaaa tccactcatt ccttgggatt attgccctat
5400ttctcgttgt gaaggtgata ccacacctac aatagtcaat ttagaccatc ccgtaatatc
5460ttgtgccaaa acgaaacaat tgcgagttgt aaatgggatt ccaacacgaa caaacatagg
5520atggatggtt agtttgagat acagaaataa acatatctgc ggaggatcat tgataaagga
5580gagttgggtt cttactgcac gacagtgttt cccttctcga gacttgaaag attatgaagc
5640ttggcttgga attcatgatg tccacggaag aggagatgag aaatgcaaac aggttctcaa
5700tgtttcccag ctggtatatg gccctgaagg atcagatctg gttttaatga agcttgccag
5760gcctgctgtc ctggatgatt ttgttagtac gattgattta cctaattatg gatgcacaat
5820tcctgaaaag accagttgca gtgtttatgg ctggggctac actggattga tcaactatga
5880tggcctatta cgagtggcac atctctatat aatgggaaat gagaaatgca gccagcatca
5940tcgagggaag gtgactctga atgagtctga aatatgtgct ggggctgaaa agattggatc
6000aggaccatgt gagggggatt atggtggccc acttgtttgt gagcaacata aaatgagaat
6060ggttcttggt gtcattgttc ctggtcgtgg atgtgccatt ccaaatcgtc ctggtatttt
6120tgtccgagta gcatattatg caaaatggat acacaaaatt attttaacat ataaggtacc
6180acagtcatag
6190145190DNAArtificial SequenceSynthetic Hepatocyte Growth Factor
Hybrid (HGF)-X3 14atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct
gcatctcctc 60ctgctcccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa
tacaattcat 120gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact
gaagataaaa 180accaaaaaag tgaatactgc agaccaatgt gctaatagat gtactaggaa
taaaggactt 240ccattcactt gcaaggcttt tgtttttgat aaagcaagaa aacaatgcct
ctggttcccc 300ttcaatagca tgtcaagtgg agtgaaaaaa gaatttggcc atgaatttga
cctctatgaa 360aacaaagact acattagaaa ctgcatcatt ggtaaaggac gcagctacaa
gggaacagta 420tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc
acacgaacac 480aggtaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat
gttaacagtc 540tcatattagt ccttcagaat aattctacaa tcctaaaata acttagccaa
cttgctgaat 600tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga
ttaattaata 660tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg
tagatctcgg 720tatttgtgaa ataataacgt aaacttcgtt taaaaggatt cttcttcctg
tctttgagaa 780agtacggcac tgtgcagggg gagaggttga ttgtgaaaaa tcagaggtag
atgagaatct 840tactgagggc tgagggttct ttaaccttgg tggatctcaa cattggttgc
acattaaaat 900cacctgctgc aagcccttga cgaatcttac ttagaagatg acaacacaga
acaattaaat 960cagaatctct ggggagaata gggcaccagt attttttgag ctcccaccat
gattccaaag 1020tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc
agcttttcca 1080tctcacctat cgcctaaaga ccaaattgga taaatgtgtt cattacgaca
gatgggtact 1140atttaaagat gagtaaacac aatatactta ggctcgtcag actgagagtt
ttaatcatca 1200ctgaggaaaa acatagatat ctaatactga ctggagtatt agtcaaggct
tatttcacac 1260acaattttat cagaaaccaa agtagtttaa aacagctctc cccttattag
taatgcattg 1320gagggtttac tttaccatgt accttgctga gcactgtacc ttgttaatct
catttacttg 1380taatgagaac cacacagcgg gtagttttat tggttctatt ttacctacat
gacaaaactg 1440aagcataaaa acacttagta agttttcagt gtcatgcaca actaggaagt
gacatggcca 1500gaatataagc ccagtcacca tcactctata acctgcgctt ttaacaactt
cagggcatga 1560cacatttggc cggtcagtag aacccatgct gtgatttgtt tttgcagtgg
tggtgatgac 1620tgccttgttg aatccacttt ttattctatt ccattttggg gacacaattc
tgcaagatga 1680ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa
gagtttgttg 1740ctccacactg ggattaaacc tatgatcttg gcctaattaa cactagctag
taagtgtcca 1800agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa
attagttact 1860tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca
aaaacaaaaa 1920ttataattgg ttttgtcctc ttttgagagt ttgcatggtg ttactccctg
catagtgaag 1980aaaacatttt atttaagtag atggatctaa gtttttcatg aacaaaggaa
tgacatttga 2040aatcaatcct accctagtcc aggagaatgc attagattaa cctagtagag
gtcttatttc 2100accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa
atagatctct 2160ctgggaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc
cttgtgatat 2220agatgtttat ggccgagagg atcctgggta ggaaacacat ttgaatggta
tttactaaga 2280tactaaaatc cttggacttc actctaattt tagtgccatt tagaactcaa
ggtctcagta 2340aaagtagaaa taaagcctgt taacaaaaca caaactgaat attaaaaatg
taactggatt 2400ttcaaagaaa tgtttactgg tattacctgt agatgtatat tctttattat
gatcttttgt 2460gtaaagtctg gcagacaaat gcaatatcta attgttgagt ccaatatcac
aagcagtaca 2520aaagtataaa aaagacttgg ccttttctaa tgtgttaaaa tactttatgc
tggtaataac 2580actaagagta gggcactaga aattttaagt gaagataatg tgttgcagtt
actgcactca 2640atggcttact attataaacc aaaactggga tcactaagct ccagtcagtc
aaaatgatca 2700aaattattga agagaataag caattctgtt ctttattagg acacagtaga
tacagactac 2760aaagtggagt gtgcttaata agaggtagca tttgttaagt gtcaattact
ctattatccc 2820ttggagcttc tcaaaataac catataaggt gtaagatgtt aaaggttatg
gttacactca 2880gtgcacaggt aagctaatag gctgagagaa gctaaattac ttactggggt
ctcacagtaa 2940gaaagtgagc tgaagtttca gcccagattt aactggattc tgggctcttt
attcatgtta 3000cttcatgaat ctgtttctca attgtgcaga aaaaaggggg ctatttataa
gaaaagcaat 3060aaacaaacaa gtaatgatct caaataagta atgcaagaaa tagtgagatt
tcaaaatcag 3120tggcagcgat ttctcagttc tgtcctaagt ggccttgctc aatcacctgc
tatcttttag 3180tggagctttg aaattatgtt tcagacaact tcgattcagt tctagaatgt
ttgactcagc 3240aaattcacag gctcatcttt ctaacttgat ggtgaatatg gaaattcagc
taaatggatg 3300ttaataaaat tcaaacgttt taaggacaga tggaaatgac agaattttaa
ggtaaaatat 3360atgaaggaat ataagataaa ggatttttct accttcagca aaaacatacc
cactaattag 3420taaaattaat aggcgaaaaa aagttgcatg ctcttatact gtaatgatta
tcattttaaa 3480actagctttt tgccttcgag ctatcggggt aaagacctac aggaaaacta
ctgtcgaaat 3540cctcgagggg aagaaggggg accctggtgt ttcacaagca atccagaggt
acgctacgaa 3600gtctgtgaca ttcctcagtg ttcagaagtt gaatgcatga cctgcaatgg
ggagagttat 3660cgaggtctca tggatcatac agaatcaggc aagatttgtc agcgctggga
tcatcagaca 3720ccacaccggc acaaattctt gcctgaaaga tatcccgaca agggctttga
tgataattat 3780tgccgcaatc ccgatggcca gccgaggcca tggtgctata ctcttgaccc
tcacacccgc 3840tgggagtact gtgcaattaa aacatgcgct gacaatacta tgaatgacac
tgatgttcct 3900ttggaaacaa ctgaatgcat ccaaggtcaa ggagaaggct acaggggcac
tgtcaatacc 3960atttggaatg gaattccatg tcagcgttgg gattctcagt atcctcacga
gcatgacatg 4020actcctgaaa atttcaagtg caaggaccta cgagaaaatt actgccgaaa
tccagatggg 4080tctgaatcac cctggtgttt taccactgat ccaaacatcc gagttggcta
ctgctcccaa 4140attccaaact gtgatatgtc acatggacaa gattgttatc gtgggaatgg
caaaaattat 4200atgggcaact tatcccaaac aagatctgga ctaacatgtt caatgtggga
caagaacatg 4260gaagacttac atcgtcatat cttctgggaa ccagatgcaa gtaagctgaa
tgagaattac 4320tgccgaaatc cagatgatga tgctcatgga ccctggtgct acacgggaaa
tccactcatt 4380ccttgggatt attgccctat ttctcgttgt gaaggtgata ccacacctac
aatagtcaat 4440ttagaccatc ccgtaatatc ttgtgccaaa acgaaacaat tgcgagttgt
aaatgggatt 4500ccaacacgaa caaacatagg atggatggtt agtttgagat acagaaataa
acatatctgc 4560ggaggatcat tgataaagga gagttgggtt cttactgcac gacagtgttt
cccttctcga 4620gacttgaaag attatgaagc ttggcttgga attcatgatg tccacggaag
aggagatgag 4680aaatgcaaac aggttctcaa tgtttcccag ctggtatatg gccctgaagg
atcagatctg 4740gttttaatga agcttgccag gcctgctgtc ctggatgatt ttgttagtac
gattgattta 4800cctaattatg gatgcacaat tcctgaaaag accagttgca gtgtttatgg
ctggggctac 4860actggattga tcaactatga tggcctatta cgagtggcac atctctatat
aatgggaaat 4920gagaaatgca gccagcatca tcgagggaag gtgactctga atgagtctga
aatatgtgct 4980ggggctgaaa agattggatc aggaccatgt gagggggatt atggtggccc
acttgtttgt 5040gagcaacata aaatgagaat ggttcttggt gtcattgttc ctggtcgtgg
atgtgccatt 5100ccaaatcgtc ctggtatttt tgtccgagta gcatattatg caaaatggat
acacaaaatt 5160attttaacat ataaggtacc acagtcatag
5190
User Contributions:
comments("1"); ?> comment_form("1"); ?>Inventors list |
Agents list |
Assignees list |
List by place |
Classification tree browser |
Top 100 Inventors |
Top 100 Agents |
Top 100 Assignees |
Usenet FAQ Index |
Documents |
Other FAQs |
User Contributions:
Comment about this patent or add new information about this topic: